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1. GENERAL INTRODUCTION AND OUTLINE OF THE THESIS 
 
 
For its critical position between the systemic circulation and the blood flow of the 
gastrointestinal tract – mediated by the portal vein – the liver plays an essential 
role in the intermediary metabolism, transforming dietary nutrients into the major 
chemical elements crucial for life and human health. Conversely, many nutrients 
and the overall dietary composition can influence liver function. In fact, an 
excessive intake of refined carbohydrate and saturated fats, an increased 
consumption of fructose and other simple sugars, and the spread of high-calorie 
Western diets have been associated with a dramatic increase in overweight/obesity 
and insulin resistance and, more recently, also with non-alcoholic fatty liver 
disease (NAFLD) [1]. Noteworthy, the excess of adiposity, in particular 
abdominal adiposity, and insulin resistance are the major contributors to the 
development of several cardiometabolic abnormalities strictly related to the 
increased risk of cardiovascular disease (CVD) and type 2 diabetes mellitus 
(T2DM). Interestingly, it is important to underline that the most recent evidence 
from longitudinal studies suggests that NAFLD itself can be considered as an 
independent cardiometabolic risk factor beyond the classical cardiometabolic risk 
factors [2]. Currently, lifestyle interventions – including strategies to reduce body 
weight and to increase regular physical activity – represent the mainstay of 
NAFLD management. Total caloric intake plays a very important role in the 
development of NAFLD; however, apart from the caloric restriction alone, 
modifying the quality of the diet – modulating either the macro or micronutrient 
composition – can also markedly affect the clinical evolution of NAFLD, offering 
a more realistic and feasible treatment alternative.  
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Recently, considerable interest has been placed on the possible beneficial effect of 
some dietary components on NAFLD. Generally, hypercaloric diets, especially 
rich in trans/saturated fat and cholesterol, high consumption of red and processed 
meat, and fructose-sweetened beverages seem to increase the risk of NAFLD 
development, whereas a high consumption of foods or beverages rich in bioactive 
compounds of plant origin, such as whole grains, legumes, fruits, vegetables, nuts, 
coffee and tea, have shown preventive and therapeutic effects on NAFLD. The 
relationship between the intake of some dietary components and the improvement 
in NAFLD could be related, at least in part, to some bioactive compounds able to 
improve glucose and lipid metabolism, insulin resistance, hepatic fat content, sub-
clinical inflammatory status, and oxidative stress. 
Consequently, it is conceivable that the combination of these foods in a dietary 
model such as a "Portfolio diet", inspired to a Mediterranean Diet model in which 
more beneficial dietary component are included – i.e. low glycemic index (GI) 
carbohydrates, vegetable fiber, monounsaturated fatty acids (MUFA), n-6 and n-3 
polyunsaturated fatty acids (PUFA), polyphenols, and vitamins – could maximize 
the impact on prevention and treatment of NAFLD.  
In this scenario, it is important to define which dietary components are able to 
prevent and treat NAFLD to design dietary interventions to test. Therefore, the 
present project was designed to assess: (1) the relationships between liver fat 
content and metabolic, inflammatory and nutritional factors in a homogeneous 
cohort of individuals at high cardio-metabolic risk; (2) the effects of fructose 
intake on liver fat content and other cardiometabolic risk factors in a large cohort 
  
3 
 
of abdominally obese men; (3) the effects of a Portfolio diet versus an 
isoenergetic diet rich in MUFA on liver fat content in patients with T2DM. 
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2. OVERVIEW ON NON-ALCOHOLIC FATTY LIVER DISEASE 
 
2.1. NAFLD definition 
NAFLD is characterized by an excessive accumulation of lipids in >5% of hepato-
cytes, primarily in the form of triglycerides, in the absence of a considerable 
alcohol ingestion (ethanol intake ≤30 g/day for men and ≤20 g/day for women), 
and ruling out other causes of liver injury, i.e. hepatitis B/C virus infection, drugs 
assumption or environmental toxins, genetic or metabolic diseases, extrahepatic or 
nutritional conditions [3]. The term NAFLD incorporates an extensive spectrum 
of histologic liver abnormalities, varying from simple triglyceride accumulation in 
hepatocytes – non-alcoholic fatty liver (NAFL) or steatosis – to non-alcoholic 
steatohepatitis (NASH), characterized by the additional presence of inflammation 
and tissue injury. NASH can evolve to fibrosis, which can lead to cirrhosis and 
hepatocellular carcinoma [4].  
 
2.2. NAFLD and cardiometabolic risk  
NAFLD is the most common chronic liver disease in the industrialized world with 
a 15–30% prevalence reported in the general population [5]. Interestingly, based 
on the diagnostic criteria utilized and the clinical characteristics of the different 
populations, its prevalence varies widely. In particular, the prevalence of NAFLD 
is very high in individuals at high cardiometabolic risk. Cardiometabolic risk 
refers to a condition associated with an increased risk of developing CVD and 
T2DM as a consequence of the presence of interrelated alterations in metabolic 
and vascular functions, as well as dyslipidemia, hypertension, abdominal obesity, 
insulin resistance and hyperglycemia. All these abnormalities identify the 
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metabolic syndrome; consequently, the close association between NAFLD and the 
metabolic syndrome is not surprising [6,7]. In line with these observations, the 
prevalence of NAFLD is approximately 50% in hypertensive subjects, 70% in 
people with T2DM, and up to 90% in severely obese patients [8-10]. 
Dramatically, NAFLD is also the most prevalent form of chronic liver disease in 
childhood and very recent data indicate that nearly 70-80% of obese children may 
have NAFLD [11]. Given the increasing prevalence of obesity and metabolic 
syndrome, NAFLD will become one of the most important public health 
challenges in the next decades for its related complications. In particular, it should 
be considered that simple NAFL can progress to NASH in about 20-25% of cases, 
and nearly 20% of patients with NASH can develop fibrosis and cirrhosis [12]; in 
patients with cirrhosis, the cumulative incidence of hepatocellular carcinoma 
ranges from 2.4% to 12.8% over 3-7 years [13]. Beyond the liver-related 
complications, it is important to underline that NAFLD is also an emerging risk 
factor for T2DM and CVD [14,15], and that it has recently been associated with 
an increased risk of chronic kidney disease [16].  
 
2.3. Pathogenesis of NAFLD   
The mechanisms involved in NAFLD development and progression are not 
completely clear. The hypothesis of the “two-hit” model – for the first time 
proposed by Day et al. in 1998 – in the pathogenesis of NAFLD has been 
accepted for about one decade [17]. According to this model, the “first hit” is 
characterized by the accumulation of lipids – primarily in the form of triglycerides 
derived from esterification of free fatty acids and glycerol – in the hepatocytes. 
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The increased triglyceride liver content can be considered as a form of ectopic 
lipid accumulation, a condition strongly related to the imbalance between influx, 
synthesis, β-oxidation and export of free fatty acids in the liver [18]. In particular, 
Donelly et al. clearly observed that 59% of the triglycerides present in the liver of 
patients with NAFLD derived from free fatty acids released from adipose tissue, 
26% from de novo lipogenesis, and 15% from dietary lipids [19]. Also important 
is the low rate of β-oxidation of free fatty acids and the reduction in triglyceride 
export by very low density lipoprotein particles in a liver with increased fat 
content [20]. Insulin resistance plays a pivotal role in the “first-hit” and in liver 
triglyceride accumulation increasing the free fatty acids release from adipose 
tissue, reducing the glucose uptake from the skeletal muscle and favoring the 
hepatic influx of these metabolites; furthermore, insulin resistance increases de 
novo lipogenesis and reduces the synthesis and secretion of very low density 
lipoprotein [21].  
The increase in liver triglyceride content is strongly associated with hepatocyte 
susceptibility to the damage promoted by the “second hit”. The “second-hit” can 
be promoted by lipid peroxidation, oxidative stress, inflammatory cytokines, and 
mitochondrial dysfunction. All together, these factors induce steatohepatitis and 
can lead to fibrosis, which can evolve to cirrhosis [22]. 
In the last few years, based on a large body of knowledge, the hypothesis of the 
“two-hit” model has been translated into the “multiple-hit” model. In fact, it 
appears reasonable that the simple “two hit” mechanism is too reductive and 
inadequate to explain the complex mechanisms involved in NAFLD development 
and progression; furthermore, only a minority of patients with NAFLD progress to 
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NASH or cirrhosis [1], and, on the other hand, steatohepatitis can be the initial 
alteration observed in the liver [23]. In fact, it has been observed that some 
patients with NASH have only a modest liver triglyceride content [23], suggesting 
that inflammation – in some conditions – can be the primum movens of the 
process.  
The “multiple-hit” model provides a comprehensive model that takes into account 
the multiple factors and interactions involved in NAFLD [24]. Based on this 
model, dietary habits, insulin resistance, visceral adiposity, inflammatory state, 
oxidative stress, alteration in gut microbiome, and genetic predisposition, are all 
recognized risk factors for NAFLD development and progression. 
In particular, the type of diet, other environmental factors and genetic 
predisposition play an important role in the development of insulin resistance, 
visceral obesity, and gut microbiome changes.  Insulin resistance promotes 
steatosis with the mechanisms above discussed; adipose tissue is involved – 
beyond the free fatty acids efflux – in the production and secretion of the 
inflammatory cytokines and adipokines involved in NAFLD progression [25]. 
Changes in the gut microbiome related to dietary habits can influence energy 
homeostasis and systemic inflammation [24]; all these factors can aggravate 
oxidative stress and endoplasmic reticulum stress in hepatocytes, leading to 
hepatic inflammation [26]. Furthermore, genetic predisposition of single 
nucleotide polymorphisms in genes like Patatin-Like Phospholipase 3 (PNPLA3) 
or in Transmembrane 6 Superfamily Member 2 (TM6SF2) can aggravate liver 
injury [27], (Figure 1).  
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With respect to the strong relation between genetic predisposition and dietary 
habits, NAFLD represents an optimal example of disease by which nutrigenomics 
has allowed us to understand how nutrients can influence its development and 
progression by altering the expression of genes involved in inflammation, glucose 
and lipid metabolism [28]. 
 
Figure 1. Pathogenesis of NAFLD. 
 
Based on the “multiple hit” model, dietary habits, insulin resistance, visceral adiposity, 
inflammatory state, oxidative stress, alteration in microbiome, and genetic predisposition, are all 
recognized risk factors for NAFLD. DNL: de novo lipogenesis; FFA: free fatty acids; IL-6: 
interleukin-6; IL-1β: interleukin-1β; LPS: lipopolysaccharide; NAFLD: non-alcoholic fatty liver 
disease; NASH: non-alcoholic steatohepatitis; TNF-α: tumor necrosis factor-α. 
 
Nutrigenomics focuses on identifying and understanding molecular interactions 
between nutrients/dietary bioactive compounds with the genome [29]. With regard 
to NAFLD, the PNPLA3 I148M polymorphism is a clear example of these 
possible interactions: individuals with the PNPLA3 I148M polymorphism are 
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more prone to develop steatosis when the intake of carbohydrates, in particular 
simple sugars, is elevated [30]. Briefly, PNPLA3 exerts a lipolytic activity on 
triglycerides and its up-regulation is mediated by carbohydrates [31]; in 
individuals with the PNPLA3 I148M polymorphism, high intake of carbohydrates 
induces the accumulation of the pathological protein – less able to hydrolyze the 
triglycerides – on the surface of lipid droplets and a consequent decreased 
secretion of triglyceride-rich lipoproteins from the liver [32]. Based on these 
observations individualized nutritional strategy takes into account also the genetic 
features of individuals may be more effective in the clinical management of 
NAFLD. 
 
2.4. Diagnosis of NAFLD   
Liver biopsy is still the gold standard for the diagnosis of NAFLD, and this 
invasive procedure – despite some limitation related to sampling variability and 
procedural potential risk – discerns simple NAFL from NASH [33]. However, in 
large population assessment or for disease monitoring, some non-invasive markers 
have been proposed. In terms of biochemical markers, it should be considered that 
serum levels of alanine aminotransferase (ALT) and aspartate aminotransferase 
(AST) are inaccurate markers of NAFLD and only moderately correlate with liver 
fat content [33].  
For the identification of NAFL the best validated scores are represented by: the 
fatty liver index [34], the NAFLD liver fat score [35] and the Steato test [36], 
based on some biochemical markers and clinical parameters as liver enzymes, 
body mass index (BMI), waist circumference, presence of T2DM or metabolic 
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syndrome. In terms of instrumental evaluation, the first-step is represented by 
ultrasonography (US) [37,38], although it is limited by the possible interference of 
liver fibrosis on bright liver echo pattern and the very low sensitivity and 
specificity in individuals with BMI >40 kg/m2. CT presents similar accuracy for 
NAFLD as US; however, it is limited by radiation exposure [33]. The proton 
magnetic resonance spectroscopy (1H-MRS) can reveal a liver fat content as low 
as 1%, but it is limited by its high cost [33]. In terms of biochemical markers, 
cytokeratin-18 (CK-18) fragments, derived from hepatocytes apoptosis or death, 
are only modestly accurate; therefore, for the diagnosis of NASH, liver biopsy is 
still the only diagnostic procedure [39]. Several scores based on biochemical 
parameters have been proposed to evaluate liver fibrosis as. NAFLD Fibrosis 
Score, Fibrosis 4 Calculator, Enhanced Liver Fibrosis, and the Fibro Test are the 
most utilized [40]. Transient elastography is the instrumental imaging performed 
for the evaluation of liver fibrosis, but it has a high rate of false positive results 
[41].  
 
2.5. Management of NAFLD: hypocaloric diet and physical activity   
At present, lifestyle intervention – including strategies to reduce body weight and 
increase regular physical activity – represents the mainstay of NAFLD 
management. Recently, the Clinical Practice Guidelines for the management of 
NAFLD – proposed by a joint effort of the European Association for the Study of 
the Liver, the European Association for the Study of Obesity, and the European 
Association for the Study of Diabetes – recommended a 7–10% body weight loss 
in overweight/obese patients with NAFLD as a target to achieve [33,42]. A 
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similar target is proposed by the American Association for the Study of Liver 
Diseases [2].  
Body weight loss in NAFLD can be achieved by hypocaloric diet alone or in 
combination with increased physical activity. 
Although total calorie intake plays a very important role in both the development 
and the treatment of NAFLD, only modulating the quality of the diet, i.e. 
changing both the macro and the micronutrient composition, can also markedly 
affect the clinical evolution of NAFLD offering a more realistic and feasible 
treatment alternative.  
To this regard, the Mediterranean diet – characterized by high consumption 
of olive oil as source of added fat, legumes, whole grains, fruits, vegetables, and 
fish; a low consumption of dairy products and meat; and a moderate alcohol 
assumption [43] – could represent an adequate therapeutic approach in NAFLD 
prevention and treatment and this dietary pattern has been recently recommended 
as appropriate for the management of NAFLD [33].  
The beneficial effect of Mediterranean diet on many metabolic chronic diseases is 
largely supported by several epidemiological studies [44]. Recently, Zelber-Sagi 
et al. have comprehensively reviewed the evidence on this aspect [45] concluding 
that the adherence to the Mediterranean diet was significantly related to an 
improvement of NAFLD. 
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3. DIET COMPOSITION AND NON-ALCOHOLIC FATTY LIVER      
    DISEASE IN ISOCALORIC CONDITIONS  
 
3.1. Dietary fatty acids 
3.1.1. Saturated fatty acids  
Saturated fatty acids (SFA) contain no double bonds in the straight-chain 
hydrocarbon with varying length ranging from short chain length (volatile liquids) 
to chain lengths of 30 or more carbon atoms (waxy solids). The main food sources 
are animal fat products such as cream, cheese, butter, other whole milk dairy 
products and fatty meats and eggs, but also some vegetable fat, i.e. coconut and 
palm kernel oils.  
Observational studies focusing on dietary habits of patients with NASH have 
suggested the possible negative influence of SFA, since their diets were richer in 
SFA than in other fatty acids compared to subjects with simple liver steatosis [46] 
or to the general population [47].   
Along this line, controlled intervention trials demonstrated that increasing dietary 
SFA in isocaloric substitution of carbohydrates [48] or PUFA [49] increased 
hepatic and visceral fat accumulation in healthy subjects.  
The detrimental effect of SFA on liver fat may be mediated by the increase in 
insulin resistance and oxidative stress, both associated with NAFLD. To date, 
studies in vitro and in animal models have shown that SFA could induce 
lipogenesis by promoting the transcription of peroxisome proliferator-activated 
receptor-gamma (PPAR-γ) coactivator-1β and the sterol regulatory element-
binding transcription factor 1c (SREBP-1c). In addition, they promote oxidative 
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stress, and apoptosis of hepatocytes [50,51], possibly leading to the progression of 
NAFLD to NASH [52]. 
 
3.1.2. Monounsaturated fatty acids and n-6 polyunsaturated fatty acids 
MUFA contain one double bond in their aliphatic hydrocarbon chain. MUFA are 
mainly found in plant-based foods such as olive oil, canola oil, nuts, soy and 
avocado, and to a lesser extent in red meat and whole milk products.  
PUFA contain more than one double bond in their chemical structure. There are 
two main PUFA groups with relevant biological functions and they are classified 
by the position of their first double bond counting from the methyl carbon: n-6 
PUFA with their first unsaturated bond at carbon6 and n-3 PUFA at carbon3; their 
main dietary sources are flaxseed and some nuts. 
Albeit scanty, the evidence available to date shows quite clearly the impact of 
MUFA on liver fat (Table 1). After an 8-week intervention with a high-MUFA 
diet (28% of total energy) vs. a high-carbohydrate/high-fiber/low–glycemic index 
diet (MUFA 16% of total energy), a 29% reduction of liver fat content, measured 
by 1H-MRS, was observed in a group of T2DM subjects in comparison to a 
baseline diet moderately rich in SFA (13% of total energy) [53].    
An even greater reduction (-39%) was observed in only 6 weeks by Ryan and 
colleagues [54] in a group of T2DM subjects with NAFLD assigned to an 
isocaloric Mediterranean diet (MUFA intake 23% of total energy) vs a low-
fat/high-carbohydrate diet (MUFA intake 8% of total fat). In a long-term 
intervention trial (24 weeks) [55], olive oil (MUFA 70%) and canola oil (MUFA 
61%) consumption was compared to control oil (soybean or safflower oil such as 
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the most common oil used in the habitual diet, MUFA 15–24%) showing a 
remarkable reduction of fatty liver grading evaluated by US, with 66.7% and 
76.7% of the participants in the olive and canola oil groups, respectively, 
reverting to normal liver grading after the intervention. 
Although the evidence is rather convincing, the exact mechanism through which 
MUFA could affect hepatic triglycerides content is not completely clear. In in 
vitro and in vivo studies, MUFA have been shown to activate peroxisome 
proliferator-activated receptor-alfa (PPARα) and PPARγ [48], increasing lipid 
oxidation [57-59] and inhibiting lipogenesis [58,60], thus leading to a reduction in 
hepatic steatosis (Figure 2). On the other hand, MUFA can promote fatty acid 
deposition in adipose tissue rather than in the liver, enhancing the clearance of 
circulating triglyceride rich lipoproteins by lipoprotein lipase [61] with an 
improvement in blood lipid profile, insulin resistance and obesity-related 
inflammation [62,63]. As for the effect of n-6 PUFA on NAFLD, only one study 
has been conducted (Table 1). In a 10-week isocaloric randomized and controlled 
trial [64], participants were assigned either to a PUFA diet (sunflower oil and 
seeds) or to a saturated fat diet. After the intervention, liver steatosis assessed by 
1H-MRS was significantly reduced with the PUFA diet compared to the SFA diet 
(-26% vs. +8%, respectively).  
Therefore, we can conclude that MUFA and n-6 PUFA seem to have beneficial 
effects on liver fat content in individuals at high cardiometabolic risk.  
As for the possible mechanisms, PUFA are key regulators of the transcription of 
genes associated with lipid metabolism and mitochondrial β-oxidation (i.e. PPAR-
  
15 
 
α and SREBP-1). Thus, increasing PUFA intake may lead to a reduction of 
lipogenesis in favor of an increased hepatic fatty oxidation [65] (Figure 2). 
 
Figure 2. Possible sites of action of dietary nutrients in the nutritional treatment 
and prevention of NAFLD.  
 
Nutrients and dietary composition can modulate many key aspects in the pathophysiology of 
NAFLD: simple sugars promote DNL, produce inflammation and activate cellular stress pathways. 
Contrarily, LGI meals can improve insulin resistance and can positively modulate the microbiome. 
SFA could induce lipogenesis, oxidative stress, and apoptosis of hepatocytes; conversely, MUFA 
and PUFA can improve FFA β-oxidation and can reduce DNL, improve insulin sensitivity and 
reduce inflammation. Polyphenols could inhibit DNL and increase FFA β-oxidation. Furthermore, 
polyphenols can improve insulin sensitivity, reduce the transcription of inflammatory cytokines, 
and can mitigate the oxidative stress involved in NAFLD progression. Vitamin C and vitamin E 
could avoid the progression of NAFLD and improve NASH acting as powerful antioxidants; 
furthermore, vitamin E could reduce plasma levels of cytokines involved in inflammation and liver 
fibrosis. Vitamin D can reduce the transcription of inflammatory cytokines and improve FFA β-
oxidation. Furthermore, it has been observed that vitamin D increases adiponectin secretion, 
decreases lipolysis in adipose tissue, and improves insulin resistance. DNL: de novo lipogenesis; 
LGI: low glycemic index; MUFA: monounsaturated fatty acids; NAFLD: non-alcoholic fatty liver 
disease; NASH: non-alcoholic steatohepatitis; PUFA: polyunsaturated fatty acids; SFA: saturated 
fatty acids 
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Table 1. Clinical trials on the effects of MUFA and n-6 PUFA on NAFLD in 
individuals at high cardiometabolic risk. 
 
Author 
[reference] 
Study 
design 
Study 
population 
Participants 
Age 
BMI 
Intervention 
and doses 
 
Duration 
weeks 
 
Observed effects 
with MUFA or n-6 PUFA 
Liver 
imaging 
Liver 
biomarkers 
Liver 
scores 
Liver 
Biopsy 
MUFA 
Bozzetto 
et al. 2012 
[53] 
Randomized, 
controlled, 
parallel 
group  
36 M/F, 
T2DM 
58.7 years 
29.7 kg/m2 
MUFA diet 
(MUFA 28% TE) 
vs 
high-CHO/fiber/ 
low–GI diet  
(MUFA 16% TE) 
8 
↓ LIVER  
FAT 
(1H-
MRS) 
AST = 
ALT = 
n.a. n.a. 
Ryan et al.  
2013 
[54] 
Randomized, 
controlled, 
crossover  
12 M/F, 
T2DM 
55.0 years 
32.0 kg/m2 
Mediterranean 
diet  
(MUFA 23% TE) 
vs  
low fat-high 
CHO  
(MUFA 8% TE ) 
6 
↓ LIVER 
 FAT 
(US) 
AST = 
ALT = n.a. n.a. 
Nigam et 
al. 2014 
[55] 
Randomized, 
controlled, 
parallel 
group  
93 M 
37.0 years 
27.4 kg/m2 
olive oil  
(MUFA 70%) 
vs  
canola oil 
(MUFA 61%) 
vs 
soybean or  
safflower oil  
(MUFA 15–
24%TE) 
24 
↓ LIVER 
 FAT 
(US) 
AST = 
ALT = n.a. n.a. 
n-6 PUFA 
Bjermo et 
al. 2012 
[64] 
Randomized, 
controlled, 
parallel 
group  
61 M/F 
56.5 years 
30.2 kg/m2 
PUFA diet  
(linoleic acid 15% 
TE) 
vs  
SFA diet  
(butter 15% TE) 
10 
↓ LIVER  
FAT 
(1H-
MRS) 
AST n.a. 
ALT = n.a. n.a. 
TE: total energy; = no changes; ↓ significant decrease.  
BMI: body mass index; MUFA: monounsaturated fatty acids; n-6 PUFA: n-6 polyunsaturated fatty 
acids; vs: versus; T2DM: type 2 diabetes mellitus; M: male; F: female; CHO: carbohydrates; GI: 
glycemic index; SFA: saturated fatty acids; 1H-MRS: proton magnetic resonance spectroscopy; 
ALT: alanine aminotransferase; AST: aspartate aminotransferase; n.a.: not assessed; US: 
ultrasonography.  
 
3.1.3. n-3 polyunsaturated fatty acids 
As reported above, n-3 PUFA is one of the two main PUFA groups with relevant 
biological functions. The most biologically relevant n-3 PUFA are α-linolenic 
acid (ALA), eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA). The 
main dietary sources of n-3 PUFA are fish oil, flaxseed and some nuts. Several 
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studies on n-3 PUFA supplementation and NAFLD are available in individuals at 
high cardiometabolic risk. Overall, the available evidence still produces 
conflicting results (Table 2). 
In a 24-week intervention trial, a complete fatty liver regression was observed 
after a 2 g/day of n-3 PUFA supplementation in the context of an American Heart 
Association (AHA) diet in 33.4% of the patients [66]. These findings were further 
confirmed by the results of the WELCOME study showing that the 
supplementation with 4 g/day of PUFA over 18 months significantly affected liver 
fat content in a dose-dependent manner as compared vs. placebo [67].  
 
Table 2. Clinical trials on the effects of n-3 PUFA on NAFLD in individuals at 
high cardiometabolic risk. 
 
Author 
[reference] 
Study design Study 
population 
Participants 
Age 
BMI 
Intervention 
and doses 
 
Duration 
weeks 
 
Observed effects 
with n-3 PUFA 
Liver 
Imaging 
Liver 
biomarkers 
Liver 
scores 
Liver 
biopsy 
Spadaro 
et al. 
2008  
[66] 
Parallel 
group 
randomized, 
controlled 
36 M/F 
50.1 years 
30.5 kg/m2 
2g/day  
vs. 
placebo 
24 
↓ LIVER  
FAT 
(US) 
AST = 
ALT ↓ 
n.a. n.a. 
Scorletti et 
al. 
2014 
[67] 
Double- 
blind, 
placebo- 
controlled  
103 M/F 
51.5 years 
33.0 kg/m2 
4g/day  
(EPA 1.8 g, 
DHA 1.5 g) 
vs. 
placebo 
72 
↓ LIVER  
FAT 
(MRI) 
AST = 
ALT = n.a. n.a. 
Zhu et al.  
2008 
[68] 
Double- 
blind, 
placebo- 
controlled 
134 M/F 
44.5 years 
26.2 kg/m2 
6g/day  
vs. 
placebo 24 
↓ LIVER  
FAT 
(US) 
AST = 
ALT ↓ n.a. n.a. 
Vega et al. 
2008 
[69] 
Crossover 
placebo- 
controlled 
16 M/F 
50.0 years 
36.2 kg/m2 
9g/day  
(EPA 51.4%, 
DHA 23.9%) 
vs. 
placebo 
8 
= LIVER 
 FAT 
(1H-MRS) 
AST n.a. 
ALT n.a. 
n.a. n.a. 
Argo et al.  
2015 
[70] 
Double- 
blind, 
placebo- 
controlled 
34 M/F 
46.8 years 
32.5 kg/m2 
3 g/day 
(EPA 35%, DHA 
25%)  
vs. 
placebo 
48 
= LIVER  
FAT 
(MRI) 
AST = 
ALT = 
n.a. = NASH 
score  
Sanyal et 
al.  
2014 
[71] 
Double- 
blind, 
placebo- 
controlled 
243 M/F 
48.7 years 
34.8 kg/m2 
EPA 1.8 g/day 
vs. 
EPA 2.7 g/day  
vs. 
48 n.a. 
AST = 
ALT = n.a. 
= NASH 
score 
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placebo 
Cussons 
et al.  
2009 
[72] 
Crossover  
placebo- 
controlled 
25F 
54.5 years 
34.8 kg/m2 
4 g/day 
(EPA 27%,  
DHA 56%) 
vs. 
placebo 
(oleic acid 67%) 
8 
= LIVER  
FAT 
(1H-MRS) 
AST n.a. 
ALT = 
n.a. n.a. 
= no changes; ↓ significant decrease. 
BMI: body mass index; M: male; F: female; n-3 PUFA: n-3 polyunsaturated fatty acids; US: 
ultrasonography; n.a.: not assessed; MRI: magnetic resonance imaging; ALT: alanine 
aminotransferase; AST: aspartate aminotransferase; DHA: docosahexaenoic acid; EPA: 
eicosapentaenoic acid; 1H-MRS: proton magnetic resonance spectroscopy; NASH: non-alcoholic 
steatohepatitis. 
 
Similarly, increasing the amount of n-3 PUFA to 6 g/day vs placebo, in the 
context of an AHA diet, induced a full reversion of liver steatosis in 19.7% of 
participants, and an overall improvement of fatty liver grading in 53% of the study 
population after a 24-week intervention [68].  
In contrast with the above studies, an 8-week supplementation with 9 g/day of fish 
oil vs. placebo did not affect hepatic triglyceride content measured by 1H-MRS 
[69]; similarly, Argo et al. [70] did not detect any improvement of fatty liver in a 
group of subjects receiving 3g/day of fish oil for 12 months as compared with the 
placebo group. On the same line, a 12-months supplementation with EPA had no 
significant effects on the key features of NASH [71].  
Cussons and colleagues [72] compared the effects of the daily consumption of n-3 
PUFA or MUFA in a group of women with polycystic ovary syndrome, a 
condition associated with NAFLD. According to an 8-week crossover randomized 
and controlled trial, they consumed 4 g/day of n-3 PUFA and a placebo. Both 
arms reduced liver fat measured by hepatic 1H-MRS. 
As reported above, the efficacy of n-3 PUFA supplementation on liver fat content 
is still controversial. This lack of concordance may be due, at least in part, to the 
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largely different doses used in the trials (ranging from 0.25 to 6 g/day), the length 
of the exposure (from 2 to 18 months), and last but not least the imaging methods 
(US vs. 1H-MRS). Nevertheless, the only two studies looking at NASH features 
on liver biopsies showed no effect of n-3 PUFA.  
To date, evidence of the mechanisms linking n-3 PUFA supplementation and 
NAFLD derives mainly from in vitro and animal studies. First of all, as reported 
for n-6 PUFA, increasing PUFA intake may increase fatty oxidation in the liver 
through the modulation of PPAR-α and SREBP-1 [65]. On the other hand, EPA 
and DHA are important modulators of the inflammatory pathway and, 
consequently, may inhibit pro-inflammatory eicosanoid production by 
inflammatory cells related to hepatic injury in NAFLD (Figure 2). 
 
3.2. Carbohydrates 
3.2.1. Low glycemic-index carbohydrate and fibre rich diets 
The association between high carbohydrate intake, high GI carbohydrate 
consumption, insulin resistance and liver fat accumulation has been found in 
animal models and observational studies [73,74]. In particular, in a cross-sectional 
study, the prevalence of high-grade liver steatosis increased significantly across 
quartiles of high GI versus low GI diets [75]. In fact, available carbohydrates 
produce an increase in serum levels of glucose in the postprandial state that can be 
used for the synthesis of new triglycerides through de novo lipogenesis in the liver 
[76]. The consumption of foods with high GI promotes insulin resistance, a 
condition strongly related to NAFLD [77], and the negative effect of a high GI 
diet on liver fat content can be observed in few days [78]. Conversely, low GI 
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meals could have beneficial effect on NAFLD. In fact, low GI foods, especially 
foods rich in fibre, can decrease glucose absorption, reducing hepatic influx of 
glucose and de novo lipogenesis [79]; in addition, the fibre content of low GI 
foods can positively act on the gut microbiome, a possible mediator by which 
nutrients may influence liver fat content [80] (Figure 2).  
Although GI seems to be an important factor in NAFLD prevention and treatment, 
few clinical trials have investigated the effect of low GI or low glycemic load 
(GL) at isocaloric conditions on NAFLD in patients at high cardiometabolic risk 
(Table 3).  
 
Table 3. Clinical trials on the effects of different types of carbohydrates (low 
glycemic index diet, oligofructose, simple sugars) on NAFLD in individuals at 
high cardiometabolic risk. 
 
Author 
[reference] 
Study 
Design 
Study 
population 
Participants 
Age 
BMI 
Intervention 
and doses 
 
Duration 
weeks 
 
Observed effects 
with carbohydrates, oligofructose and simple 
sugars 
Liver 
Imaging 
Liver 
biomarkers 
Liver 
scores 
Liver 
biopsy 
Low glycemic index diet 
Fraser  
et al.  
2008 
[84] 
Open label,  
quasi- 
randomized, 
controlled 
259 M/F 
T2DM 
56 years 
31.5 kg/m2 
ADA diet  
(CHO: 50-55%, 
fat: 30%, protein: 
20%) 
or 
LGI diet 
(CHO: 50-55%, 
fat: 30%, protein: 
15-20%) 
or 
MM diet 
(CHO: 35%, fat: 
45%, protein: 15-
20%) 
52 n.a.  ALT ↓ n.a. n.a. 
Utzschnei
der et al.  
2012 
[81] 
Randomized  
parallel, 
double- 
bind, 
 
35 M/F 
68.9 years 
27.5 kg/m2 
 
LSAT diet  
(23% fat, 7% 
saturated fat, 
GI<55) 
vs 
HSAT diet 
(43% fat, 24% 
saturated fat, 
GI>70) 
4 
↓ LIVER  
FAT  
(1H-MRS) 
AST = 
ALT = 
n.a. n.a. 
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Ramon- 
Krauel et 
al.  
2013 
[83] 
Randomized 
parallel 
 
16 M/F 
12.8 years 
32.6 kg/m2 
 
LGI diet  
(CHO: 40%, fat: 
35-40%, protein: 
15-20%) 
vs 
LF diet  
(CHO: 55-60%, 
fat: 30%, protein: 
15-20%) 
24 
= LIVER  
FAT  
(1H-MRS) 
AST = 
ALT = 
 
n.a. n.a. 
Misciagna 
et al. 2016 
[82] 
Randomized 
parallel- 
group, 
controlled  
98 M/F 
47.5 years 
31.5 kg/m2 
 
LGI diet 
(CHO: 50%, fat: 
30%, protein: 15-
20%) 
vs  
control 
(diet based on 
INRAN 
guidelines) 
24 
↓ LIVER  
FAT  
(US) 
AST = 
ALT = n.a. n.a. 
Oligofructose 
Daubiol et 
al.  
2005 
[89] 
 
Randomized 
double- 
blind, 
crossover 
controlled 
7 M  
NASH 
54.5 years 
29.1 kg/m2 
Oligofructose  
(16 g/day)  
vs  
maltodextrine 
8 
= LIVER 
 FAT 
 (US) 
AST ↓ 
ALT = n.a. n.a. 
Fructose/Simple sugars                                                           
Johnston 
et al.  
2011 
[110] 
 
Randomized 
double- 
blind 
 
32 M 
33.9 years 
29.4 kg/m2 
 
Fructose (25% 
TE) 
vs  
Glucose (25% 
TE)  
2 
= LIVER  
FAT 
(1H-MRS) 
AST = 
ALT = n.a. n.a. 
Bravo et 
al.  
2013 
[103] 
 
Randomized 
parallel- 
group 
64 M/F 
42.1 years 
27.2 kg/m2 
 
HFCS  
(8%, 18% or 30% 
of the calories 
required for 
weight 
maintenance) 
vs 
Sucrose 
(8%, 18% or 30% 
of the calories 
required for 
weight 
maintenance) 
10 
= LIVER  
FAT 
 (CT) 
n.a. n.a. n.a. 
Maersk et 
al.  
2012 
[102] 
 
Randomized 
parallel- 
group 
47 M/F 
38.7 years 
32.0 kg/m2 
 
Regular cola (1 
L/day) 
or 
Milk (1 L/day) 
or 
Diet cola (1 
L/day) 
or 
Water (1 L/day) 
24 
↑ LIVER  
FAT 
(1H-MRS) 
n.a. n.a. n.a. 
TE: total energy; = no changes; ↓ significant decrease; ↑ significant increase. BMI: body mass 
index; M: male; F: female; T2DM: type 2 diabetes mellitus; ALT: alanine aminotransferase; AST: 
aspartate aminotransferase; n.a.: not assessed; ADA: American Diabetes Association; CHO: 
carbohydrates; LGI: low glycemic index; MM: Mediterranean modified; US: ultrasonography; 1H-
MRS: proton magnetic resonance spectroscopy; CT: computed tomography; LGI: low glycemic 
index; INRAN: Italian National Research Institute for Foods and Nutrition; LSAT: low-fat/low-
saturated fat/low-glycemic index diet; HSAT: high-fat/high-saturated fat/high-glycemic index diet; 
GI: glycemic index; LF: low fat; HFCS: high-fructose corn syrup. 
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Three studies evaluated the effects of low GI diets on liver fat compared to diets 
with higher GI, and two of them found a significant reduction in liver fat – 
evaluated by 1H-MRS in one and by US in the other [81,82]; no change was 
observed in the third study performed in obese children [83]. In none of these 
three studies was there any change with respect to liver enzymes; on the other 
hand, a reduction in ALT was reported after a low GI diet and a Mediterranean 
diet compared to a control diet in one intervention trial performed in patients with 
T2DM in which only liver enzymes were analyzed [84]. 
The fibre content of foods is one of the most important factors related to GI. 
Dietary fibre is defined as a non-digestible food carbohydrates; based on water 
solubility it can by classified into soluble – pectins, fructans, oligosaccharides and 
gums – and insoluble – hemicellulose, cellulose and lignin – and it is widely 
found in fruits, vegetable, whole grains and legumes [85]. Some epidemiological 
studies have shown that fibre intake in NAFLD patients is lower than in healthy 
individuals [86-88]. 
However, if we exclude the trials in which fibre was part of multifactorial dietary 
changes, only limited research regarding the effects of fibre alone on NAFLD has 
been done. We have found only one study evaluating the effects of a non-
digestible carbohydrate, oligofructose (Table 3). In this trial, a decrease in ALT 
and AST was found after 16 g of oligofructose compared to maltodextrine in 
patients with NASH although no change in liver fat was detected at US [89]. 
Trying to draw some conclusions from the trials evaluating the effects of low GI 
diets on NAFLD, the few data available indicate that the low GI may have some 
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role within the context of a diet characterized by other favorable changes such as, 
in primis, the reduction of saturated fatty acids.   
 
3.2.2. Fructose/other simple sugars  
The intake of simple sugars increases liver fat content in animal models [90,91] 
and epidemiological studies suggest an association between consumption of soft 
drinks and NAFLD development in humans [92-94].  
Simple sugars, in particular fructose, has been shown to promote hepatic 
lipogenesis by stimulating SREBP-1c and carbohydrate response element-binding 
protein (ChREBP), the major transcription factors of many enzymes involved in 
de novo lipogenesis [95-97]. Furthermore, it has been observed that fructose and 
glucose consumption – in addition to stimulating SREBP-1c and ChREBP – may 
produce inflammation and activate cellular stress pathways [98,99] (Figure 2).  
Many clinic trials have investigated the effect of simple sugars – mainly fructose, 
glucose and sucrose – on NAFLD in healthy individuals and in those at high 
cardiometabolic risk [100-107], and two meta-analyses on this issue were carried 
out [108,109]. Briefly, the first meta-analysis reported that in healthy subjects 
using high doses of fructose – in terms of 104-220 g/day – in a hypercaloric diet 
increased both liver fat content and serum ALT levels while did not produce any 
effect in isocaloric conditions [108]. Similar findings were reported by the second 
meta-analysis where it was observed that the excess of added sugar intake in a 
hypercaloric diet compared with a eucaloric control diet increased liver fat content 
[109]. Only three trials have looked specifically at the effect of simple sugars 
intake as part of an isocaloric diet in overweight/obese subjects (Table 3).  
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Johnston et al. investigated the effects of glucose- or fructose-sweetened 
beverages providing 25% of energy requirements during an isocaloric period of 2 
weeks. At the end of treatment, in overweight patients with NAFLD, serum ALT 
and AST levels, and liver fat content evaluated by 1H-MRS were unchanged 
[110]. Similar findings were reported by Bravo et al. who investigated the effects 
of three different levels of sucrose or high-fructose corn syrup (55% fructose) at 
8%, 18%, or 30% of the calories required for weight maintenance in overweight 
patients with NAFLD. At the end of 10-week intervention, liver fat content 
evaluated by CT was unchanged [103]. On the other hand, Maersk et al. compared 
the effects of four different drinks – 1 L/day of regular cola, or isocaloric semi-
skim milk, or aspartame-sweetened diet cola or water – in obese subjects with 
NAFLD. After 24 weeks of treatment, drinking regular cola resulted in a higher 
amount of liver fat content, evaluated by 1H-MRS [102].  
In conclusion, even if data are still limited, it seems that simple sugars, at least 
within the context of an isocaloric diet, do not have a marked deleterious 
influence on liver fat in overweight individuals, while frankly obese subjects may 
be more sensitive to the exposure to simple sugars even within an isocaloric diet. 
 
3.3. Proteins 
Limited evidence on the effect of proteins on NAFLD is available. In animal 
models, a reduction in liver fat content was observed when protein intake was 
increased [111].  
A very recent analysis of The Rotterdam Study, a large epidemiological study, 
showed that total protein intake, in particular proteins of animal origin, was 
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associated with higher odds of NAFLD in overweight subjects (OR= 1.50; 95% 
CI 1.17-1.92) [112]; similarly, a cross-sectional evaluation of the Israeli National 
Health and Nutrition Survey showed that the intake of meat was significantly 
associated with an increased risk for NAFLD (OR= 1.37, 95% CI 1.04–1.83) 
[113]. The effect of protein intake on NAFLD has been evaluated only in few 
controlled clinical trials, generally adopting hypocaloric diets [114-116]. 
Therefore, it is not possible to draw any conclusion about the possible effect of 
proteins per se on NAFLD.  
 
3.4. Other dietary components 
3.4.1. Polyphenols 
Polyphenols represent a great variety of secondary plant metabolites and, based on 
their chemical structure, they can be divided into two major categories: flavonoid 
and non-flavonoids. About 8.000 phenolic compounds in the plant kingdom have 
been discovered. Vegetables, cereal grain, fruits, and some beverages – tea, 
coffee, red wine, beer – are good sources of polyphenols [117]. Mean total dietary 
intake of polyphenols was 1193 ± 510 mg/day [118]. These natural compounds 
are powerful antioxidants, in addition to having many other properties such as 
anti-inflammatory, anti-mutagenic, and immunomodulatory activities [117]. 
Phenolic compounds have received growing interest over the last few years and 
epidemiological studies have shown an inverse correlation between high 
polyphenol consumption and incidence of many chronic metabolic diseases, 
including obesity, insulin resistance, and CVD [119]. A randomized controlled 
trial in individuals at high cardiometabolic risk showed that diets naturally rich in 
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polyphenols improved fasting and postprandial dyslipidemia and reduced 
oxidative stress [120]. Recently, beneficial effects of polyphenols on NAFLD 
have been reported in animal models [121]. 
Polyphenols could prevent liver fat accumulation and NAFLD progression 
through several mechanisms. In in vitro and animal models it has been observed 
that polyphenols may reduce hepatic lipogenesis and increase free fatty acid 
oxidation. In particular, polyphenols can decrease the transcription of SREBP-1c 
[122] and increase transcription of PPAR-α. Moreover, polyphenols can improve 
insulin sensitivity and reduce the transcription of inflammatory cytokines [123-
125]. All these molecular pathways can be indirectly modulated by the effect of 
polyphenols on the activation of AMP-activated protein kinase [126]. Finally, the 
antioxidant properties of phenolic compounds in reducing oxidative stress 
involved in NAFLD progression should be also considered [121] (Figure 2). 
Whereas from these animal and in vitro studies it can be argued that polyphenols 
may have positive influence on different aspects of NAFLD, the controlled 
intervention trials in humans have produced discordant results (Table 4). 
The effects of mixed phenolic compounds have been investigated by two trials 
[127,128]. Chang et al. [127] evaluated in overweight NAFLD patients the effects 
of 150 mg/day of polyphenols compared to placebo. After 12 weeks of treatment, 
in the polyphenol group a significant 15% reduction in fatty liver score was 
observed, with no changes in AST or ALT levels. In a trial conducted by Guo et 
al. [128], young NAFLD patients were given 250 mL of bayberry juice or placebo 
twice daily for 4 weeks. No significant differences in the serum levels of AST and 
ALT between the groups were observed.  
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Table 4. Clinical trials on the effects of polyphenols supplementation on NAFLD 
in individuals at high cardiometabolic risk. 
 
Author 
[reference] 
Study design Study 
population 
Participants 
Age 
BMI 
Intervention 
and doses 
 
Duration 
weeks 
 
Observed effects 
with polyphenols 
Liver 
imaging 
Liver 
biomarkers 
Liver 
scores 
Liver 
biopsy 
Suda et al.  
2008 
[129] 
 
Double-blind, 
randomized,  
placebo- 
controlled  
38 M 
43.0 years 
25.4 kg/m2 
 
Anthocianins  
(400 mg/day) 
vs 
placebo 
8 n.a.  AST n.a. 
ALT ↓ 
n.a. n.a. 
Sakata et al.  
2013 
[130] 
 
Double-blind, 
randomized,  
placebo- 
controlled 
17 M/F 
50.6 years 
29.0 kg/m2 
Cathechin  
(1.080 mg/day) 
vs 
placebo 
12 
↓ LIVER  
FAT  
(CT) 
AST n.a. 
ALT ↓ 
 
n.a. n.a. 
Chang et al.  
2013 
[127] 
 
Double-blind, 
randomized,  
placebo- 
controlled 
36 M/F 
37.9 years 
31.2 kg/m2 
 
Flavonoids,  
anthocyanins, 
phenolic acid 
(150 mg/day) 
vs 
placebo 
12 
↓ LIVER 
FAT  
(US) 
AST = 
ALT = ↓ FS n.a. 
Guo et al.  
2014 
[128] 
 
Double-blind, 
randomized, 
crossover,  
placebo- 
controlled  
44 M/F 
21.2 years 
25.4 kg/m2 
 
Phenolic acids,  
anthocyanins 
(1,350 mg/day) 
vs 
placebo  
4 n.a.  
 
AST = 
ALT = 
TPS ↓ 
CK-18 ↓ 
n.a. n.a. 
Poulsen et 
al.  
2013 
[131] 
 
Double-blind, 
randomized,  
placebo- 
controlled 
24 M 
38.3 years 
34.2 kg/m2 
Resveratrol  
(500 mg/day) 
vs 
placebo 
4 
= LIVER 
 FAT 
(1H-MRS) 
AST n.a. 
ALT = n.a. n.a. 
Faghihzadeh 
et al. 2014 
[134] 
 
Double-blind, 
randomized,  
placebo- 
controlled 
50 M/F 
45.1 years 
28.5 kg/m2 
 
Resveratrol 
(500 mg/day) 
vs 
placebo 12 
↓ LIVER  
FAT 
(US) 
 
= LIVER  
FIBROSIS 
(TEL) 
AST = 
ALT ↓ 
CK-18 ↓ 
n.a. n.a. 
Chychay et 
al. 2014 
[133] 
 
Double-blind, 
randomized,  
placebo- 
controlled 
20 M 
48.1 years 
31.5 kg/m2 
 
Resveratrol 
(3,000 mg/day) 
vs 
placebo 
8 
= LIVER 
 FAT 
(1H-MRS)  
AST* ↑ 
ALT* ↑ 
CK-18 = 
n.a. n.a. 
Chen et al.  
2014 
[123] 
 
Double-blind, 
randomized,  
placebo- 
controlled  
60 M/F 
44.3 years 
25.7 kg/m2 
 
Resveratrol 
(600 mg/day) 
vs 
placebo 
12 
= LIVER 
 FAT 
(US) 
AST ↓ 
ALT ↓ 
CK-18 ↓ 
FGF-21↓ 
n.a. n.a. 
Heebøll et 
al.  
2016 
[132] 
 
Double-blind, 
randomized,  
placebo- 
controlled 
28 M  
(46% NASH) 
43.3 years 
31.9 kg/m2 
Resveratrol  
(1,500 mg/day) 
vs 
placebo 
24 
= LIVER 
 FAT 
(1H-MRS) 
 
AST = 
ALT = 
 
n.a. = 
NASH 
 
* at week 6; = no changes; ↓ significant decrease; ↑ significant increase. BMI: body mass index; 
M: male; F: female; ALT: alanine aminotransferase; AST: aspartate aminotransferase; n. a.: not 
assessed; US: ultrasonography; CT: computed tomography; 1H-MRS: proton magnetic resonance 
spectroscopy; TEL: transient elastography; FS: fatty liver score; CK-18: Cytokeratin-18; FGF-21: 
fibroblast growth factor 21; NASH: non-alcoholic steatohepatitis. 
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Two more trials evaluated the effects of specific polyphenols, such as 
anthocyanins and catechins. Authors observed a significant reduction in the serum 
levels of ALT versus placebo [129]. In the second study, the consumption of the 
highest dose of catechins significantly decreased serum ALT level by 42.1% and 
improved liver fat content with a liver-to-spleen CT attenuation ratio that 
increased from 92% to 102% [130]. 
Resveratrol is currently one of the more extensively studied polyphenols, and five 
trials have been conducted on NAFLD. In two of these studies resveratrol at the 
dose of 500 mg/day and 1,500 mg/day, respectively, did not induce any change in 
the different liver outcomes evaluated [131,132]. In another intervention trial, 
where a higher dose of resveratrol was used – 3,000 mg/day – a transient increase 
in ALT and AST was observed at week 6, with no change at the end of the 
intervention in liver enzymes or in liver fat [133]; conversely, two trials showed 
some beneficial effects [123,134].  
Therefore, based on these data, catechins and antocianins seem to have some 
beneficial influence on liver fat, but this needs to be confirmed by additional 
evidence. As for resveratrol, the results are so discordant that no definite 
conclusion can be drawn.  
 
3.4.2. Vitamin E 
The term vitamin E refers to eight lipid-soluble compounds – four tocotrienols 
and four tocophenols – with powerful antioxidant properties. These essential 
vitamins are synthesized in vegetables and are largely present in seeds, nuts, 
vegetable oils, green leafy vegetables and fortified cereals [135, 136]. Vitamin E 
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plays a key role in many physiological functions: it is one of the most powerful 
antioxidant and acts as free radical scavenger; it is also involved in the regulation 
of platelet aggregation, protein kinase C activation, immune function, gene 
expression, and other metabolic processes [137].  
Vitamin E could avoid the progression of NAFLD and improve NASH by virtue 
of its antioxidant capacity and as free radical scavenger. It has been observed that 
vitamin E reduces the inflammatory pathway in NASH by several mechanisms, 
beyond its “simple” antioxidant activity; in particular, vitamin E could improve 
superoxide dismutase activity and could decrease the transcription of many genes 
related to inflammation and liver fibrosis [138-141]; it has been also reported that 
vitamin E could improve insulin sensitivity [142] (Figure 2).  
The possible effects of vitamin E supplementation on NAFLD have been assessed 
in different intervention trials and the results of these trials have been examined in 
two meta-analyses [143,144]. Briefly, vitamin E supplementation in patients with 
NAFLD reduces significantly liver enzymes, liver steatosis, inflammation and 
hepatocellular ballooning compared to control treatments. Moreover, in patients 
with NASH, vitamin E supplementation seems to reduce fibrosis as well. Despite 
the positive results of these meta-analyses, it is important to underline some 
limitations such as the variability in daily dosage of vitamin E, the length of 
treatment, and the small sample size of the studies, except for the PIVENS and the 
TONIC studies [145,146]. Furthermore, some concerns must be underlined about 
the possible negative effects of high doses of vitamin E (>400 IU/day) on all-
cause mortality [147]. 
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3.4.3. Vitamin C 
Vitamin C is a soluble vitamin and its major dietary forms – L-ascorbic and 
dehydroascorbic acids – are largely found in vegetables and fresh fruits [148]. 
Vitamin C plays a key role in many physiological functions for human health – it 
is essential for the activity of the enzymes implicated in the synthesis of 
catecholamines, carnitine and collagen – and, in addition, it is a powerful 
antioxidant and acts as a free radical scavenger [149].  
In the last few years, a noteworthy epidemiological literature has shown an 
inverse correlation between vitamin C deficiency and some chronic diseases, as 
obesity, hypertension, and CVD [150]. The results of epidemiological studies are 
conflicting about a possible relation between vitamin C and NAFLD. In fact, 
Ferolla et al. [151] reported that patients with NAFLD were unable to achieve the 
optimal intake of vitamin C, and similar findings were reported by Musso et al. 
[47] and Canbakan et al. [152], who analyzed the intake of vitamin C in patients 
with NASH. Conversely, in other cross-sectional studies no relation between 
dietary vitamin C intake and presence of NAFDL or NASH was observed [153-
155]. These conflicting results may be related to ethnicity and differences in 
disease grade (NAFL or NASH); furthermore, it should be considered that in 
many studies the dietary intake of vitamin C was considered with no evaluation of 
plasma vitamin C levels. 
Theoretically, vitamin C could play a beneficial role in NAFLD by acting as 
powerful antioxidant and as free radical scavenger. In in vitro models, vitamin C 
can reduce reactive oxygen species formation and improve the activity of 
glutathione peroxidase and superoxide dismutase [156]. Furthermore, vitamin C 
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can promote the production of adiponectin – an adipose tissue protein apparently 
able to decrease insulin resistance and inflammation in humans [157] (Figure 2). 
To the best of our knowledge, no clinical trial has investigated the effect of 
vitamin C supplementation alone on NAFLD, while some clinical trials have 
evaluated the effects of the combination of vitamins C and E (Table 5).  
 
Table 5. Clinical trials on the supplementation of vitamins C + E on NAFLD in 
individuals at high cardiometabolic risk. 
 
Author 
[reference] 
Study 
design 
Study 
population 
Participants 
Age 
BMI 
Intervention 
and doses 
 
Duration 
weeks 
 
Observed effects 
with vitamin C plus vitamin E 
Liver 
Imaging 
Liver 
biomarkers 
Liver 
scores 
Liver 
biopsy 
Harrison 
et al.  
2003 
[164] 
 
Double-
blind, 
randomized,  
placebo- 
controlled 
45 M/F, 
NASH 
51.3 years 
32.7 kg/m2 
 
Vitamin C 
(1,000 
mg/day) 
+  
Vitamin E  
(1,000 
IU/day)  
vs  
placebo 
24 n.a. 
AST = 
ALT = 
n.a. = NASH 
↓ FIBROSIS 
Ersöz et 
al.  
2005 
[166] 
 
Open-label, 
randomized 
 
57 M/F  
(15% 
NASH) 
47.1 years 
28.4 kg/m2 
 
 
Vitamin C  
(500 mg/day)  
+  
Vitamin E  
(600 IU/day)  
vs  
UDCA 
(10 
mg/kg/day) 
24 
= LIVER 
FAT 
(US)  
AST = 
ALT = n.a. n.a. 
Nobili et 
al.  
2006 
[167] 
 
Double-
blind, 
randomized,  
placebo- 
controlled 
90 M/F  
(26% 
NASH) 
12.1 years 
25.0 kg/m2 
Vitamin C  
(500 mg/day) 
+  
Vitamin E  
(600 IU/day)  
vs  
placebo 
52 
= LIVER 
 FAT 
(US) 
AST = 
ALT = n.a. n.a. 
Nobili et 
al.  
2008 
[165] 
 
Open-label, 
randomized,  
placebo- 
controlled 
53 M/F 
11.9 years 
25.8 kg/m2 
Vitamin C  
(500 mg/day) 
+  
Vitamin E  
(600 IU/day)  
vs  
placebo 
104 n.a. 
AST = 
ALT = 
n.a. 
= LIVER 
FAT 
= NASH 
= FIBROSIS 
↓NAFLD 
activity 
score 
= no changes; ↓ significant decrease. BMI: body mass index; NASH: non-alcoholic steatohepatitis; 
M: male; F: female; ALT: alanine aminotransferase; AST: aspartate aminotransferase; n.a. : not 
assessed; UDAC: ursodeoxycholic acid; IU: international unit; US: ultrasonography; NAFLD non-
alcoholic fatty liver disease. 
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The results of these trials were not concordant, two studies showing a reduction in 
fibrosis and NAFLD activity score evaluated on liver biopsy [158,159], two 
studies showing no effects on liver fat [160,161]. 
 
3.4.4. Vitamin D 
Vitamin D is a lipid-soluble compound found in few foods such as fatty fish, fish 
liver oils, and dairy products; it is also produced in the skin after ultraviolet 
irradiation. Vitamin D2 and vitamin D3 – also defined ergocalciferol and 
cholecalciferol – are the two main forms of vitamin D. Vitamin D plays a 
prominent role in calcium and phosphorus metabolism and is essential for bone 
health, promoting bone growth and remodeling. In the last decade, it has become 
evident that vitamin D also presents extra-skeletal effects, including metabolic 
effects, neuromuscular and immune functions [162].  
A growing body of literature has shown that serum levels of vitamin D are 
inversely associated with insulin resistance, metabolic syndrome, CVD, T2DM 
and NAFLD [163-165]. A meta-analysis of observational studies showed that 
subjects with NAFLD were 26% more likely to present vitamin D deficit than 
controls [166]. Vitamin D receptors are widely expressed in the liver and can 
explain the possible effect of vitamin D on NAFLD. Vitamin D may down-
regulate the expression of the NF-κB – involved in the transcription of 
inflammatory cytokines – and improve the expression of PPAR-α in the liver 
[167]. Furthermore, it has been observed that vitamin D increases adiponectin 
secretion and decreases lipolysis in adipose tissue [168], improves the expression 
of GLUT-4 receptor in skeletal muscle [169] and promotes insulin secretion 
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[170]. All these effects – mediated by the specific vitamin D receptor – could 
reduce liver fat content (Figure 2). 
To date, very few clinical trials have investigated the effects of vitamin D 
supplementation on NAFLD (Table 6).  
 
Table 6. Clinical trials on the effects of vitamin D supplementation on NAFLD in 
individuals at high cardiometabolic risk. 
 
Author 
[reference] 
Study design Study 
population 
Participants 
Age 
BMI 
Intervention 
and doses 
 
Duration 
weeks 
 
Observed effects 
with vitamin D 
Liver 
Imaging 
Liver 
biomarkers 
Liver 
scores 
Liver 
Biopsy 
Sharifi et 
al. 2014 
[177] 
Double-blind, 
randomized,  
placebo- 
controlled, 
parallel 
53 M/F 
42.1 years 
30.3 kg/m2 
Cholecalciferol  
(3,570 IU/day)  
vs 
placebo 
 
16 
= LIVER 
FAT 
(US) 
AST = 
ALT = 
n.a. 
 
n.a. 
 
Barchetta 
et al. 2016 
[178] 
Double-blind, 
randomized,  
placebo- 
controlled 
65 M/F 
T2DM 
58.6 years 
30.0 kg/m2 
 
Cholecalciferol  
(2,000 IU/day)  
vs 
placebo 
24 
= LIVER 
FAT 
(1H-
MRS) 
AST = 
ALT = 
CK-18 = 
P3NP = 
= FLI n.a. 
Lorvand 
Amiri et 
al. 2016 
[179] 
Double-blind, 
randomized,  
placebo- 
controlled 
73 M/F 
41.9 years 
30.3 kg/m2 
Cholecalciferol  
(1,000 IU/day)  
+  
hypocaloric 
diet 
vs 
placebo  
+ 
hypocaloric 
diet 
12 
↓ LIVER 
FAT 
(US) 
AST ↓ 
ALT ↓ n.a. n.a. 
= no changes; ↓ significant decrease.BMI: body mass index; M: male; F: female; T2DM: type 2 
diabetes mellitus; ALT: alanine aminotransferase; AST: aspartate aminotransferase; n.a.: not 
assessed; US: ultrasonography; 1H-MRS: proton magnetic resonance spectroscopy; IU: 
international unit; CK-18: Cytokeratin-18; P3NP: N-terminal Procollagen III Propeptide; FLI: 
fatty liver index. 
 
Two of them [171,172] showed no effect of vitamin D supplementation on liver 
enzymes, liver fat content or hepatic biomarkers of injury and fibrogenesis. In the 
third one [173], the effect of vitamin D supplemented to a hypocaloric diet was 
evaluated in comparison to a hypocaloric diet. Liver enzymes and liver fat content 
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– evaluated by US – were significantly reduced by vitamin D independently of 
weight loss, which was similar in the two groups. 
 
In conclusion, based on the available evidence in humans, we can conclude that 
data are reasonably convincing as for the possible effects of dietary 
macronutrients on liver fat content. In fact, SFA increase liver fat content and 
replacing SFA with MUFA or n-6 PUFA reduces liver fat, while the effectiveness 
of n-3 PUFA supplementation is still controversial. In terms of other dietary 
components (polyphenols) and micronutrients, data are not yet convincing, and 
any effect would refer especially to liver inflammation and fibrosis more than to 
fat content. As for the role of dietary vitamins on NAFLD prevention, only for 
vitamin E supplementation, data are rather convincing even if there might be 
concerns on high vitamin E supplementation – considering its possible negative 
effects on all cause-mortality. 
Therefore, precise recommendations on the composition of the diet to be used for 
the prevention and treatment of NAFLD have not been proposed. More carefully 
conducted intervention studies are needed: it is very likely that the “optimal diet” 
for NAFLD should be based on different dietary modifications, i.e. a 
multifactorial diet or “Portfolio diet”, able to act both on the deposition of excess 
fat in the liver and the other pathways leading from liver fat deposition to NASH 
and fibrosis. However, this hypothesis needs to be substantiated by appropriate 
intervention studies in humans. 
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4. AIM AND PERSONAL RESEARCH AREAS 
NAFLD is the most prevalent chronic liver disease. Evidence supports that dietary 
pattern may play a pivotal role in the development of NAFLD. However, there is 
no consensus regarding the best dietary intervention for its prevention or 
treatment. In this scenario, it is important to define which dietary components are 
useful to prevent and treat NAFLD in order to design dietary interventions with 
higher adherence and efficacy in the management of the disease. Consequently, 
my personal research area has covered three major experimental lines:  
1. To evaluate in a more comprehensive and multifactorial manner the 
relationship of liver fat with metabolic, dietary and inflammatory factors 
in a cohort of individuals characterized by high cardiovascular risk with no 
evidence of hepatic disease and with homogenous anthropometric 
characteristics and nutritional habits (HETHERPATHS cohort). 
2. To assess the effects of fructose (75 g day/ for 12 weeks in the form of 
drink together with the habitual ad libitum diet) on liver fat content in a 
large cohort of abdominally obese men with other cardiometabolic risk 
factors (FRUCTOSE trial). 
3. To evaluate the effects of 8-weeks intervention with an isoenergetic 
Portfolio diet rich in MUFA, n-3 and n-6 PUFA, prebiotic fibre, 
polyphenols, vitamins, and low  GI carbohydrates versus an isoenergetic 
diet rich in MUFA (control diet) on liver fat content in patients with 
T2DM and NAFLD (MEDEA trial). 
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5. CLINICAL TRIALS 
 
5.1. HETHERPATS cohort 
Background 
NAFLD is an independent risk factor for CVD [14,15]. However, the cause of the 
relationships between NAFLD, other metabolic diseases and cardiovascular risk 
are not clear. Many nutritional, metabolic and inflammatory factors have been 
advocated as putative mechanisms for these associations and, therefore, for 
NAFLD pathogenesis. High caloric intake predisposes to liver steatosis and is also 
the main cause of other cardiovascular risk factors independently associated with 
fatty liver disease such as obesity and T2DM [4]. Beside over-nutrition, 
qualitative nutritional factors can play an important role in modulating liver fat 
content [3]. Among the metabolic factors, insulin resistance showed the strongest 
association with liver fat in many studies [21]. Moreover, since the prevalence of 
NAFLD is much higher in T2DM [10], also β-cell dysfunction may play a role in 
the natural history of fatty liver [174,175]. Recently, attention has been paid also 
to a possible role of GLP-1 [176]. Treatment with GLP-1 analogs ameliorated 
liver steatosis, suggesting that also gastrointestinal hormones may play a role in 
its pathogenesis [177]. Alterations of fasting and postprandial lipoprotein 
metabolism may also contribute to hepatic fat accumulation [21]. The role of 
inflammation in the natural history of NAFLD has been extensively discussed in 
the last few years [24,17]. The association between NAFLD and most of the 
above mentioned factors has been investigated in previous studies generally 
focusing on different, selected aspects of this complex issue.  
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Aim 
In the present study, we aimed to evaluate with a more comprehensive, 
multifactorial manner the relationship of liver fat with metabolic, dietary and 
inflammatory factors in a cohort of individuals characterized by high 
cardiovascular risk with no evidence of hepatic disease and with homogenous 
anthropometric characteristics and nutritional habits. 
 
Materials and Methods 
Subjects. Eighty-six individuals of both sexes, aged 35e70 y, with overweight or 
obesity (BMI 27-35 m/kg2), high waist circumference (men > 102 cm, and women 
>88 cm) and meeting at least one criterion for metabolic syndrome diagnosis 
according to the NCEP/ATP III [178], were recruited at the obesity outpatient 
clinic of the Federico II University Hospital in order to participate in a nutritional 
intervention study [120]. Data presented in this paper refer to the subjects who 
underwent liver fat evaluation by ultrasound at baseline (n=70). Exclusion criteria 
were: fasting plasma triglycerides ≥400 mg/dl, fasting cholesterol >270 mg/dl, 
cardiovascular events (myocardial attack or stroke) during the 6 months prior to 
the study, T2DM, and regular intensive exercise. The participants had no evidence 
of A, B, or C virus or autoimmune hepatitis; clinical signs or symptoms of inborn 
errors of metabolism; history of toxins or drugs known to induce hepatitis or any 
other chronic disease; or use of drugs able to influence inflammation and lipid and 
glucose metabolism (including statins). Inclusion and exclusion criteria were 
assessed by interviews, clinical examination and routine laboratory tests. Before 
inclusion in the study, participants were screened for diabetes status by an OGTT 
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performed by capillary blood glucose testing. Then they underwent baseline 
OGTT performed by venous blood glucose testing. Only if participants had no 
diabetes at screening and baseline tests were included in the study.  
 
Study design, experimental procedures. The participants were randomly assigned 
to one of four nutritional interventions as previously described in details [120]. 
The design of the trial was approved by the Federico II University Ethics 
Committee, complied with the Helsinki Declaration guidelines, and was registered 
at Clinical-Trials.gov, trial registry #NCT01154478. All participants provided 
their written informed consent. Before the intervention, body weight, height, and 
waist circumference were measured according to standardized procedures. Dietary 
habits were evaluated from a 7-day food record filled in by participants before the 
start of the intervention and collected by an expert dietitian in occasion of the run-
in visit. After a 12-h overnight fast, the participants underwent a 75 g OGTT, with 
blood sampling at 0, 15, 30, 60, 90, 120, 150 and 180 min. Two days later, after a 
12-h overnight fast, they underwent a 1000 kcal test meal with blood sampling at 
0, 60, 120, 240 and 360 min. Test-meal composition was similar to the diet 
assigned to the subjects for the trial: (a) control, low in long chain n-3PUFA 
(LCn3, 0.94 g) and polyphenols (50 mg), (b) rich in LCn3 (2.31 g) and low in 
polyphenols (50 mg), (c) rich in polyphenols (770 mg) 
and low in LCn3 (0.92 g), or (d) rich in LCn3 (2.31 g) and polyphenols (770 mg). 
All other components of the test meals were similar. Meals were composed of 
rice, butter, parmesan cheese, bresaola, and white bread, with intakes of olive oil, 
salmon and decaffeinated green tea differing in order to obtain a similar 
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composition as the diet in the trial [120]. Blood drawn in EDTA- or EDTA and 
aprotinin (for GLP-1 assay) tubes was centrifuged and plasma stored at -80°C 
until measurement. For assessment of hepatic/renal echo intensity ratio (H/R), 
ultrasound images of both right liver lobe and right kidney were obtained in 
sagittal view with the patient in lateral position. A region of interest (ROI) of 2x2 
cm in the liver parenchyma was selected so that no blood vessels or other focal 
hypo/hyperecogenicity was crossed to obtain a sample of liver parenchyma alone, 
avoiding liver lesions. Another ROI of 0.5x0.5 cm was identified in the right renal 
cortex with no vessels, renal sinus or medulla. The mean echo intensity within the 
two ROIs was measured. Then, the average intensity of hepatic ROI was divided 
by the average intensity of renal cortex ROI to calculate the ultrasound 
hepatic/renal ratio. The use of hepatic/renal ratio for the determination of liver fat 
content was previously validated against H1-MRS [179]. 
 
Laboratory methods. Chylomicrons (Svedberg flotation unit >400) and large 
VLDLs (Svedberg flotation unit 60e400) were isolated from plasma by 
discontinuous density-gradient ultracentrifugation, as previously described [180]. 
HDLs were isolated from plasma by the phosphotungstic acid/magnesium 
chloride precipitation method. LDL cholesterol was calculated by the Friedewald 
formula. Plasma glucose, cholesterol and triglyceride concentrations were assayed 
by enzymatic colorimetric methods (ABX Diagnostics, Montpellier, France; 
Roche Diagnostics, Milan, Italy) on a Cobas Mira Autoanalyzer (ABX 
Diagnostics, Montpellier, France). Plasma insulin concentrations were measured 
by an enzyme-linked immunosorbent assay (ELISA; DIAsource Immuno Assays 
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S.A., Nivelles, Belgium) on Triturus Analyzer (Diagnostics Grifols, S.A., 
Barcelona, Spain). Plasma active GLP-1 was assayed by a nonradioactive, highly 
specific sandwich enzyme-linked immunosorbent assay method (Merck-
Millipore, Darmstadt, Germany) [181]. Hs-CRP plasma concentrations were 
determined by a high sensitivity immunoturbidimetric method (Roche Molecular 
Biochemicals, Mannheim, Germany) with a functional sensitivity of 0.11 mg/L. 
Intra- and inter-assay variability were, respectively, 0.3% and 1.9%. Plasma 
interleukins and growth factors were measured using a specific kit for IL-1b, IL-4, 
IL-6, IL-10, IL-12, IL-17, TNF-α, IFN-γ, granulocyte colony-stimulating factor 
(G-CSF), basic fibroblast growth factor (FGF) and vascular endothelial growth 
(VEGF) factor (Bio-Rad Laboratories SRL, Segrate e Italy). 
 
Calculations. Fasting insulin resistance was evaluated by the homeostasis 
assessment method of the insulin resistance [HOMA-IR = (fasting glucose, mg/dl) 
x (fasting insulin, mU/l)/405] [182]. After glucose load, insulin action was 
evaluated by the 180-minutes oral glucose insulin sensitivity method (OGIS) 
[182]. Post-glucose insulin secretion capacity was calculated as β-cell function 
[insulin AUC/glucose AUC ratio] [182]. Total (AUC) and incremental (iAUC) 
areas under the curve after the glucose load and the test-meal were calculated by 
the trapezoidal method. 
 
Statistical analysis. Data are expressed as mean ± SD or median and IQR. 
Variables not normally distributed were analyzed after logarithmic 
transformation. Bivariate Pearson’s correlations were calculated to examine the 
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relation between liver fat content and metabolic, dietary and anthropometric 
variables. All variables found to correlate significantly with liver fat content, in 
addition to age, BMI, and sex were entered into a multiple regression analysis in a 
stepwise fashion having liver fat as the dependent variable. The possible influence 
of the different test-meals and the glucose tolerance status was accounted for by 
including in the model as dummy variables three indicator variables for test-meals 
(rich in LCn3, rich in polyphenols, rich in LCn3 and polyphenols) and three 
indicator variables for glucose tolerance status (IFG, IGT, IFG+IGT). The 
reference groups, that we compared the other groups against, were the control 
test-meal group and the normal glucose tolerant group, respectively. A P < 0.05 
was considered statistically significant. Statistical analysis was performed 
according to standard methods using the Statistical Package for Social Sciences 
software 20.0 (SPSS/PC; SPSS, Chicago, IL, USA).  
 
Results 
The main characteristics of our cohort are shown in Table 7. Participants were 
equally distributed between sex, and were overweight/obese and moderately 
insulin resistant as shown by HOMA-IR mean values. Twenty participants had 
impaired fasting glucose (IFG), 7 impaired glucose tolerance (IGT), and 18 IFG+ 
IGT. The average hepatic/renal ratio in the cohort was 1.43 (0.76) (median (IQR)) 
with an overall prevalence of liver steatosis of 17% considering an H/R cut-off 
point of 2.2 for steatosis diagnosis [179]. On the average, the participants had 
healthy dietary habits as shown by the composition of their habitual diet (Table 
8).  
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Table 7. Main characteristics of the participants. 
Sex (M/F)                                                      29/41 
Age (y)                                                         54 ± 9 (39-70) 
Body weight (kg)                                         86 ± 12 (60-115) 
BMI (kg/m2)                                                 31 ± 3 (25-38) 
Waist circumference (cm)                       103 ± 8 (89-127) 
Fasting plasma cholesterol (mg/dl)      195 ± 30 (124-255) 
Fasting HDL cholesterol (mg/dl)         43 ± 11 (24-72) 
Fasting LDL cholesterol (mg/dl)          118 ± 26 (71-198) 
Fasting plasma triglyceride (mg/dl)      103 (67) 
Fasting plasma glucose (mg/dl)            103 ± 11 (75-129) 
Fasting plasma insulin (mU/l)              19 ± 6 (5-32) 
HOMA-IR                                             4.8 ± 1.8 (1.0-9.5) 
IFG (n)                                                   20 
IGT (n)                                                   7 
IFG + IGT (n)                                        18 
SBP (mm Hg)                                        120 (14) 
DBP (mm Hg)                                        73 (10) 
Hepatic/renal echo intensity ratio            1.43 (0.76) 
Participants with liver steatosis (n)           12 
 
Data are M±SD (range) or median (IQR). 
HOMA-IR: homeostasis assessment method of the insulin resistance; IFG: Impaired Fasting 
Glucose; IGT: Impaired Glucose Tolerance; SBP: systolic blood pressure; DBP: diastolic blood 
pressure. 
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Table 8. Composition of the habitual diet of the study participants (n = 70) as 
evaluated by 7-day food record. 
 
Energy (kcal/day)                                          1706 (593) 
Protein (% DEI)      17 ± 2 (12-27) 
Total fat (% DEI)    33 ± 5 (20-43) 
SFA (% DEI)          10 ± 2 (6-15) 
MUFA (% DEI)      15 ± 3 (7-21) 
PUFA (% DEI)       3.8 (0.93) 
Carbohydrate (% DEI)        50 ±5 (39-62) 
Sugars (% DEI)                   17 ± 4 (38-155) 
Fiber (g/day)                        20 ± 6 (6-17) 
Vitamin C (mg/day)             103 (105) 
Vitamin E (mg/day)             8.9 (4.1) 
Polyphenols (mg/day)          552 (417) 
b-carotene (mg/day)             2192 (2239) 
FRAP (mmol eF2+/kg FW3)  187 (58) 
Alcohol (g/day)                   3.3 ± 6.7 
 
Data are M ± SD (range) or median (IQR). 
DEI: daily energy intake; MUFA: monounsaturated fatty acids; SFA: saturated fatty acids; PUFA: 
polyunsaturated fatty acids. FRAP: ferric reducing antioxidant potential. 
 
Bivariate correlations. Many anthropometric, metabolic, inflammatory and 
dietary variables were related to liver fat content (Table 9). Liver fat content was 
positively correlated with waist circumference, insulin resistance (HOMA-IR), 
fasting levels of plasma glucose and insulin, post-challenge insulin and glucose 
iAUCs and a dynamic index of β-cell function, and negatively correlated with the 
OGTT-derived index of insulin sensitivity (OGIS). Postprandial GLP-1 levels, 
either as iAUC or GLP-1 concentration 120 min after meal, were inversely related 
to hepatic/renal ratio. The pro-inflammatory cytokines and growth factors, IL-17, 
IFN-γ, IL-4, TNF-α, FGF and GCSF, but not Hs-CRP, were positively and 
significantly correlated with liver fat. Fasting HDL cholesterol was inversely 
related with liver fat. Postprandial incremental areas of cholesterol and 
triglyceride concentrations in large VLDL and total cholesterol in plasma were 
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directly associated with hepatic fat content. Among dietary factors, polyphenol, 
fiber intake, and Ferric Reducing Antioxidant Potential (FRAP) were significantly 
and negatively related with liver fat content.  
 
Multiple regression analysis. All variables that correlated significantly with liver 
fat content (Table 9) plus age, sex, BMI, test-meal type and glucose tolerance 
status were included in multiple regression analysis.  
 
Table 9. Bivariate Spearman correlations between hepatic/renal ratio and 
metabolic, inflammatory and dietary variables. 
 
Variable r coefficient p value Variable r coefficient p value 
Anthropometric parameters Dietary variables 
Body mass index 0.196 0.104 Daily energy intake 0.156 0.205 
Waist circumference 0.338 0.004 Carbohydrates (% DEI) 0.115 0.352 
Fasting glucose metabolism Sugars (% DEI) -0.120 0.328 
Plasma glucose 0.243 0.042 Protein (% DEI) -0.107 0.387 
Plasma insulin 0.410 0.000 Total fat (% DEI) -0.052 0.675 
HOMA-IR 0.433 0.000 SAFA (% DEI) 0.112 0.362 
OGTT indices MUFA (% DEI) -0.131 0.287 
Plasma glucose 3h-iAUC 0.350 0.004 PUFA (% DEI) -0.158 0.198 
Plasma insulin 3h-iAUC 0.413 0.001 n-6/n-3 -0.229 0.060 
OGIS -0.489 0.000 Polyphenols -0.258 0.034 
β-Cell Function 0.270 0.025 FRAP -0.257 0.035 
Post-prandial GLP-1 Fiber -0.284 0.019 
GLP-1 3h-iAUC -0.339 0.004 Inflammatory variables 
GLP-1 t120 -0.334 0.005 Hs-CRP 0.064 0.599 
Lipid metabolism IFN-γ 0.273 0.023 
Fasting plasma chol -0.029 0.812 IL-17 0.319 0.008 
Fasting plasma triglyceride   0.214 0.076 IL-4 0.322 0.007 
Fasting HDL chol -0.411 0.000 TNF-α 0.263 0.035 
PP plasma chol 6h-iAUC 0.270 0.024 FGF 0.299 0.017 
PP lVLDL1 chol 6h-iAUC 0.303 0.011 GCSF 0.252 0.041 
PP plasma tg 6h-iAUC 0.201 0.096  
PP VLDL1 tg 6h-iAUC 0.292 0.015 
 
DEI: daily energy intake; OGIS: oral glucose insulin sensitivity; MUFA: monounsaturated fatty 
acids; SFA: saturated fatty acids; PUFA: polyunsaturated fatty acids; FRAP: ferric reducing 
antioxidant potential; Hs-CRP: high sensitivity C-reactive protein; TNF-a: tumor necrosis factor-a; 
IFN-g: interferon-g; IL: interleukin; FGF: fibroblast growth factor; GCSF: granulocyte colony-
stimulating factor, PP: postprandial, chol: cholesterol, tg: triglycerides. 
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As shown in Table 10, OGIS was the best predictor of liver fat content predicting 
about 30% of liver fat variability. By stepwise analysis, also postprandial GLP-1, 
HDL cholesterol levels and IFN-γ were independent predictors of liver fat 
content.  
 
 
Table 10. Stepwise regression analysis of independent contribution of metabolic, 
dietary and inflammatory variables to liver fat content. 
 
 β R2 p value 
Step 1  0.341  
OGIS -0.595  0.000 
Step 2  0.450  
OGIS -0.499  0.000 
GLP-1 t120 -0.355  0.002 
Step 3  0.526  
OGIS -0.390  0.000 
GLP-1 t120 -0.381  0.000 
HDL Cholesterol -0.305  0.004 
Step 4  0.558  
OGIS -0.352  0.001 
GLP-1 t120 -0.344  0.001 
HDL Cholesterol -0.323  0.002 
IFN-γ 0.205  0.036 
 
OGIS: oral glucose insulin sensitivity; IFN-γ: interferon-γ. Variables included in the model were: 
age, BMI, sex, test-meal type, glucose tolerance status, and those founded  significantly correlated 
with liver fat at bivariate analysis as listed in Table 3. 
 
Discussion 
This study shows that in a population at high cardiometabolic risk homogeneous 
for metabolic characteristics and dietary habits, and with a relatively low 
prevalence of liver steatosis, there was a significant variability in liver fat content 
related to dietary intakes, indices of fasting and post-load glucose metabolism, 
postprandial lipid concentrations and inflammatory markers. In particular, the best 
  
46 
 
independent predictors of liver fat content in our cohort were OGIS, postprandial 
GLP-1, HDL cholesterol concentrations and fasting IFN-γ. The relationship 
between liver steatosis and insulin resistance/sensitivity has been clearly 
demonstrated by several studies in various populations with NAFLD: T2DM 
patients [10], individuals with metabolic syndrome [6], and otherwise healthy 
people [21]. Kahl et al. [183] evaluated this relationship for a range of hepatic fat 
content non diagnostic for liver steatosis showing, in line with our results, that 
both fasting and dynamic indices of glucose metabolism were strongly related 
with liver fat. Therefore, insulin-resistance may be not only a consequence of 
hepatic lipid accumulation but also one of its pathophysiological determinants. 
Interestingly, in our cohort, postchallenge insulin sensitivity (OGIS) was a better 
predictor of liver fat content than the fasting insulin resistance index (HOMA-IR). 
This may suggest that hepatic fat accumulation is mainly driven by iterative 
overflow conditions for hepatic pathways of energy clearance, such as 
postchallenge/postprandial states. 
Also fasting HDL cholesterol levels were independently associated with liver fat 
content in our cohort. Since HDL cholesterol level is a very good marker of 
insulin resistance, this could explain its strong relationship with liver fat that has 
been already reported [184]. However, in our study the relationship between liver 
fat and HDL cholesterol was independent of other factors including insulin 
resistance; therefore, other mechanisms should be considered including the higher 
catabolic rate of ApoA1 that, as recently shown, is independently associated with 
liver fat content [185]. 
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In our study, postprandial levels of GLP-1 were significantly, independently 
related to hepatic fat content. This finding – lower postprandial GLP-1 
concentrations in people with higher liver fat – is in line with previous 
observations that individuals with NAFLD had significantly lower GLP-1 levels 
after glucose load than healthy subjects [186] and treatment with GLP-1 analogs 
decreased liver fat content [177]. Moreover, in vitro and animal studies showed 
that GLP-1 has direct effects on hepatocytes through the activation of a GLP-1 
receptor regulating glucose metabolism in the liver and protecting against 
hepatocellular injuries [187]. Moreover, in human studies, the GLP-1 agonist 
exenatide inhibits postprandial absorption of chylomicrons that are a main source 
of hepatic triglyceride accumulation [188]. This would further confirm the 
“postprandial genesis” of liver steatosis. Inflammatory markers as well 
significantly predicted liver fat content in the participants in our study. Several 
previous studies reported a positive relationship between non-specific markers of 
systemic inflammation such as TNF-α, IL-6 and IL-1 and liver steatosis [24]. 
However, scanty data are available on the relationship between metabolic liver 
disease and markers of adaptive immunity. In particular, we observed that liver fat 
content correlated with circulating levels of IFN-γ independently of other factors, 
including other inflammatory markers. This observation is of particular relevance 
if we consider the recent evidence associating obesity with markers of adaptive 
immunity, particularly the activation of T-helper lymphocytes by endogenous 
stimulus, such as lipopolysaccharide deriving from gut microbiota [25,189]. This 
suggests, in line with the parallel hits hypothesis [24], that inflammation related 
with adaptive immunity activity may act as a primum movens in the natural 
  
48 
 
history of NAFLD, playing a relevant role also in accumulating fat in the liver. In 
our study, liver fat was associated also with dietary factors (dietary fiber, 
polyphenols, FRAP) and metabolic abnormalities, in primis the concentrations of 
cholesterol and triglycerides in plasma and large VLDL. These associations were 
not present at multiple regression analysis suggesting that their relationship with 
liver fat may be mediated by their strict relation with other mechanisms, such as 
insulin resistance, inflammation and GLP-1.  
This study has some strengths and limitations. A strength is that we evaluated the 
relationships between liver fat and different putative pathogenic pathways in a 
very homogeneous population of individuals at high cardiometabolic risk with a 
relatively low level of liver steatosis. The very similar characteristics of our 
participants allowed us to recognize coherent interrelationships among different 
pathophysiologic aspects, suggesting that in addition to insulin resistance, innate 
immunity and postprandial metabolism alterations also play a relevant role in the 
determinism of NAFLD. Although the cross-sectional design did not allow us to 
approach cause-effect relationship issues, the results certainly underline that 
NAFLD pathophysiology includes the vast majority of pathogenic factors 
involved in the determinism of CVD. Therefore, the clinical relevance of this 
condition is not limited to its direct health impact, but also represents the 
macroscopic synthesis of the molecular mechanisms that trigger the 
atherosclerotic process. Moreover, the higher predictive value of postprandial 
compared to fasting variables (e.g. OGIS vs. HOMA; postprandial vs. fasting 
GLP-1) suggests that the main pathophysiological pathways of liver steatosis act 
in the postprandial phase. Possible limitations of our study are the small sample 
  
49 
 
size and the fact that we did not use the gold standard for noninvasive 
measurement of liver fat, i.e. H1-MRS. However, the ultrasound hepatic/renal 
ratio was validated versus H1-MRS [179]. Moreover, all the strong and consistent 
relationships between hepatic/renal ratio and metabolic measurements observed in 
this study further confirm the method reliability. 
In conclusion, insulin resistance, systemic inflammation and postprandial GLP-1 
were the main determinants of liver fat in a selected cohort of people at high 
cardio-metabolic risk with a rather low level of liver steatosis, explaining 
altogether about 30% of liver fat variability. The different factors implicated in the 
pathogenesis of NAFLD are also involved in the pathogenesis of atherosclerosis, 
suggesting that NAFLD may represent the tip of the iceberg of the complex 
metabolic derangements leading to CVD. 
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5.2. FRUCTOSE trial 
Background 
Among nutritional factors, epidemiologic studies suggesting a possible link 
between sugar sweetened beverages and CVD risk factors such as T2DM, obesity, 
hypertension and dyslipidemia [190–197]. In addition, overconsumption of 
dietary sugars as fructose has been linked to NAFLD. Fructose has been shown to 
promote hepatic lipogenesis by stimulating SREBP-1c and ChREBP, two master 
transcriptional regulators of DNL [19, 192, 1198-200]. Fructose also leads to ATP 
depletion and suppression of hepatic mitochondrial fatty acid oxidation, thus 
favoring liver fat storage [13,95-96]. Excess consumption of fructose may also 
operate indirectly by delivering extra energy leading to weight gain and ectopic 
fat depots including liver fat content [97,190,195,197,97,201]. Recent meta-
analyses have identified several limitations in clinical studies investigating the 
adverse metabolic effects of fructose (such as small sample sizes, short 
intervention periods, variable doses of fructose intake and studies in healthy lean 
subjects with low baseline liver fat content) [202-204]. These limitations may 
explain the discrepant conclusions of the trials studying the effect of fructose 
consumption on liver fat content [201]. It appears that a hypercaloric fructose diet 
increases liver fat content in obese subjects [90]. However, it still remains unclear 
whether this is due to direct metabolic effects of fructose or merely a result of 
increased energy intake. Support for direct metabolic effects of fructose comes 
from studies showing that dietary sugars, in particular fructose, increase DNL and 
liver fat in humans [94,96,108, 205-208].  
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Aim 
The aim of this study was to assess the effects of fructose (75 g day for 12 weeks 
served as a lemonade together with habitual ad libitum diet) on liver fat content 
measured by magnetic resonance examinations in a large cohort of abdominally 
obese men with and without other cardiometabolic risk factors. We also analyzed 
changes in body composition, dietary intake, an extensive panel of 
cardiometabolic risk markers, hepatic DNL as well as responses of postprandial 
lipids to a standardized oral fat tolerance test (OFTT). 
 
Materials and Methods 
Subjects. A total of 82 obese healthy men were recruited to the study (Clinical 
Trials NCT01445730) at four centers: in Helsinki, Finland; Naples, Italy; Quebec, 
Canada; and Gothenburg, Sweden. Subjects were recruited via newspaper 
advertisements. Inclusion criteria were as follows: men with large waist 
circumference (>96 cm), BMI between 27 and 40 kg/m2, stable weight (±3 kg) 
over the preceding 3 months, low-density lipoprotein (LDL) cholesterol <4.5 
mmol/L and serum triglycerides (TG) <5.5 mmol/L. Exclusion criteria were as 
follows: age <20 years or >65 years, BMI or lipid levels outside the inclusion 
ranges, smoking, alcohol consumption over 2 doses day (i.e. 20 g pure alcohol), 
T2DM, CVD, hormonal therapy, hepatic and renal diseases, gastroenterological, 
thyroid or haematological abnormalities, and any chronic disease requiring 
medication except for controlled hypertension. None of the subjects used any 
medication or hormones known to influence lipoprotein metabolism. The study 
design was approved by the local ethics committees, and each subject gave 
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written informed consent before participation in the study. All studies were 
performed in accordance with the Declaration of Helsinki for clinical trials. 
 
Fructose intervention. Subjects underwent a 12-week fructose intervention period, 
during which they consumed 75 g of fructose daily (303 kcal), administered as 
three 330-mL bottles. The carbonated beverages were prepared as 7.6% (w/w) 
solutions and flavoured with lemon aroma (produced for this study by Nokian 
Panimo Oy, Finland). Subjects were instructed to consume the beverages together 
with the three main daily meals whilst continuing their habitual ad libitum diet 
during the intervention. The fructose-sweetened beverage was well tolerated. Of 
the 82 subjects, two subjects discontinued the intervention study: one developed a 
skin rash which was considered as possible allergic reaction to flavouring. The 
rash disappeared after the discontinuation. The other subject discontinued the 
study in response to his dentist’s advice. In addition, the data from magnetic 
resonance examinations at baseline or after the fructose intervention were not 
sufficient from nine subjects for technical reasons to allow the analyses of 
different fat depots. Thus, 71 subjects completed the full study protocol. The 
subjects’ weight and height were measured in the study center after an overnight 
fast and barefoot with underwear. The waist circumference was recorded at the 
midpoint between the lower rib margin and the iliac crest. Three consecutive 
readings were taken, and the mean was recorded. A qualified nutritionist gave 
detailed verbal and written instructions for filling in the food records. The 
compliance was assessed based on weekly reporting of adherence to fructose 
beverages on a compliance sheet where the subjects indicated the number of 
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beverages missed during the week. The dietician contacted (i.e. face to-face visits, 
phone calls or email messages) the subjects once per week to monitor weight and 
compliance. Each subject kept a 3-day food record (2 work days and 1 day off) 
before the fructose intervention period and again within 2 weeks before 
completing the intervention period. Participants were not required to weigh foods 
but were asked to measure the volume of foods consumed with household 
measurements or to indicate the weight of the products. After completing the food 
records, participants met with the local dietitians to review the food records for 
completeness. Energy and nutrient intake were calculated by linking the food 
intake information with local food composition databases. The 3-day energy and 
nutrient values were averaged to obtain mean intakes for each subject. 
 
Study design. The protocol included two separate study visits before the fructose 
intervention period: OFTT and magnetic resonance examinations. These visits 
were repeated within 2 weeks before completing the 12-week fructose 
intervention period. A standardized OFTT was performed in the morning after an 
overnight fast. The subjects received a fat-rich meal (927 kcal) consisting of 
bread, butter, cheese, ham, boiled eggs, fresh red pepper, low-fat (1%) milk, 
orange juice and tea or coffee (63 g carbohydrate, 56 g fat and 40 g protein). 
Blood samples were drawn before and at 2, 3, 4, 6 and 8 h after the meal. During 
the test, only water was allowed ad libitum and the subjects remained physically 
inactive. The participants abstained from alcohol and physical exercise for 2 days 
before each examination. In a subgroup of 56 subjects, DNL was analyzed before 
and at 4 and 8 h after the meal during the OFTT. A blood sample was drawn as a 
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background sample in the week before the OFTT. Subjects received 2 g/kg body 
weight deuterated water 2H2O (Larodan Fine Chemicals, Sweden) which was 
consumed in two servings together with evening meal on the day before the OFTT 
[209]. 1H-MRS was performed using a 1.5-T whole-body device to determine 
liver fat content [210,211]. Magnetic resonance imaging was used to determine 
subcutaneous abdominal and intra-abdominal fat expressed as volumes [212]. A 
standardized protocol was used at all centers, and all analyses of the imaging 
results were performed by one person. Subjects were advised to fast for 4 h before 
imaging. 
 
Laboratory methods. Lipoprotein fractions [chylomicrons (Sf > 400), large very 
low-density lipoprotein (VLDL1) particles (Sf 60–400) and smaller VLDL2 
particles (Sf 20–60)] from blood samples drawn before and during the OFTT were 
separated by density gradient ultracentrifugation. As all fractions contain both 
apolipoprotein (apo) B48 and apoB100 particles, they were further analyzed using 
SDS–PAGE [213]. TG and cholesterol concentrations in total plasma and in 
lipoprotein fractions were analyzed by automated enzymatic methods using the 
Konelab 60i analyzer (Thermo Fisher Scientific, Finland). Fasting and 
postprandial apoB48 levels in total plasma were measured by ELISA (Shibayagi 
Co., Shibukawa, Japan). Fasting and postprandial concentrations of glucose 
(hexokinase method, Roche Diagnostic Gluco-quant, Germany) and insulin 
(electrochemiluminescence with Roche sandwich immunoassay on a Cobas 
autoanalyser) were measured after the fat-rich meal. Plasma levels of apoC-III, 
fibroblast growth factor 21 (FGF-21) and adiponectin were measured by ELISA 
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(R&D Systems, Minneapolis, USA), and 3-hydroxybutyrate concentrations were 
measured by an enzymatic method with β-hydroxybutyrate FS kit (DiaSys 
Diagnostic Systems, Holzheim, Germany) on a Konelab 60i analyser (Thermo 
Fisher Scientific, Finland). 
 
Statistical analysis. Statistical analyses were performed using R version 3.1.1 for 
Windows, Stata (version 13.0, Stata Corporation, TX, USA) and GraphPad Prism 
version 7. For all variables, P values were calculated using the Wilcoxon signed-
rank test or the Mann–Whitney U-test. As many clinical variables could not be 
assumed to be normally distributed, these nonparametric tests were used. 
Correlation coefficients and their corresponding P values were calculated using 
Spearman’s rank test. A P value <0.05 was considered statistically significant. 
Stepwise regression analysis was performed using the ‘step’ function in R. 
Bidirectional elimination was used in the selection of variables. The 
underreporting of energy intake was evaluated by determining the ratio of 
reported energy intake to estimated basal metabolic rate (BMR). The BMR was 
estimated from the age- and gender-specific equations proposed by Schofield 
[214]. A cut-off value of 0.9 was used to identify extreme underreports of energy 
intake [215]. All analysis involving energy intake was subjected to a sensitivity 
analysis in which we excluded under reporters, but because results were virtually 
unchanged, only the results including all subjects are presented. To elucidate the 
mechanisms for the responses of liver fat to the diet intervention, we divided the 
subjects into three groups according to their change in liver fat after fructose. 
Group 1 (n = 22) had reduced liver fat content (from 7.2 ± 1.4% at baseline to 5.5 
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± 1.3% after fructose feeding), Group 2 (n = 20) had no or minimal liver fat 
change, and Group 3 (n = 29) gained liver fat (from 8.5 ± 1.2% to 11.2 ± 1.2%). 
 
Results 
Study cohort characteristics at baseline. Baseline data of the 71 men who 
completed the 12-week fructose intervention are shown in Table 11. The subjects 
showed a wide range of BMI (25.6–38.3 kg/m2), liver fat (0.3–24.8%) and other 
adiposity indices. BMI correlated modestly with visceral fat (r = 0.28, P = 0.02) 
but not with liver fat content. Visceral fat (r = 0.35, P = 0.004) but not waist 
circumference or subcutaneous fat correlated significantly with liver fat. The 
HOMA index averaged 2.8 ± 1.8% with a large range (0–8.5%) and correlated 
modestly with liver fat (r = 0.31, P = 0.008), baseline DNL (r = 0.36, P = 0.008) 
and FGF-21 (r = 0.33, P = 0.004) but not with weight or visceral fat. Baseline 
DNL also correlated with fasting insulin (r = 0.40, P = 0.003) but not with fasting 
glucose nor with liver fat content. Of the 71 participants, 27 had elevated fasting 
TG levels (>1.7 mmol/L). These men had an overall worse cardiometabolic 
profile with higher HOMA index, blood glucose, apoC-III, FGF-21, and uric acid 
and lower adiponectin than subjects with normal fasting TG levels. However, the 
two groups had comparable weight and waist circumference and did not 
significantly differ in either liver fat content (6.5±1.0% vs. 6.9 ± 0.9%) or visceral 
and subcutaneous fat depots. There was a trend for a higher VAT/SAT ratio in the 
subjects with elevated TG levels (P = 0.058). 
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Table 11. Characteristics of the study subjects (n = 71), before and after fructose feeding. The data are mean ± SD. Ranges are indicated as 
minimum and maximum values. Changes of the means after versus before are shown with ± SD. P-values have been calculated using the 
Wilcoxon signed-rank test 
 
ALT, Alaninaminotransferase; AST, aspartate aminotransferase; ALP, alkaline phosphatase. Significant of p-values <0.05 are bold. 
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Effects of fructose feeding on diet composition. Dietary intake calculated from 3-
day food records at baseline and during the fructose intervention period are shown 
in Table 12. As expected, the consumption of 75 g of fructose per day caused 
significant changes in the macronutrient composition. However, because the study 
subjects adjusted their diets, the increased energy intake during the fructose 
intervention was small (only 54 kcal) and did not reach statistical significance. 
The proportion of energy from total carbohydrates was higher, but that of sucrose, 
protein, total fat and saturated and unsaturated fatty acids was lower during the 
fructose intervention period. Although the average intake of total fat reduced 
significantly by 6.6 ± 3.3 g day, there were large variations in the individual 
changes of saturated fat intake during fructose intervention (from -33.5 to 28.6 
g/day). The energy provided by fructose was 2.5 ± 0.2% of the total energy intake 
at baseline and increased to 14.7 ± 0.3% during the intervention. During the 
fructose diet, 12.9 ± 0.3% of energy was from added fructose and 1.8 ± 0.1% of 
energy was from fructose present in the habitual diet. Intake of cholesterol, total 
fibre and alcohol was not significantly different between baseline and the fructose 
intervention period (Table 12). 
 
Effects of fructose feeding on body composition. Fructose intervention resulted in 
minor but significant increases in weight (1.1 ± 1.7%) and waist circumference 
(0.67 ± 2.5%) (Table 11). Changes in waist circumference correlated positively 
with changes in weight (r = 0.53, P < 0.001) and subcutaneous fat area (r = 0.40, P 
= 0.002) but only modestly with changes in visceral fat (r = 0.29, P = 0.02) and 
liver fat (r = 0.30, P = 0.01). There was a large variation in individual weight  
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Table 12. Reported dietary intake before and after fructose intervention. Values are shown as mean ± SD. P-values have been 
calculated using the Wilcoxon signed-rank test and refer to differences between baseline and after fructose intervention. 
 
 
EI, Energy intake. Significant of p-values <0.05 are bold. 
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Figure 3. Correlation between weight change and change of liver fat content (a), weight change and subcutaneous fat area 
change (b), and weight change and visceral fat area change (c) in response to fructose feeding. Change in subcutaneous fat 
area shows the closest correlation to weight change. 
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response to the fructose intervention: the majority (n = 37) gained weight (>1 kg), 
26 subjects remained weight stable and eight subjects lost weight (>1 kg). There 
were no significant differences in total energy intake between these three groups 
during the diet intervention and no correlation between changes of energy intake 
and body weight (data not shown). Liver fat content was increased by about 10% 
after the 12-week fructose intervention (6.7 ± 0.7 vs. 7.3 ± 0.8%, P < 0.01), but no 
significant changes were seen in visceral or subcutaneous fat depots (Table 11). 
There was a positive correlation between changes in liver fat and weight (r = 0.26, 
P = 0.03) after fructose feeding (Figure 3a). Notably, changes of subcutaneous fat 
correlated strongly with changes of weight (r = 0.46, P < 0.001) (Figure 3b), but 
no correlation was observed between changes of visceral fat and weight (r = 0.16, 
NS). Changes of liver fat content correlated also with respective changes of waist 
circumference (r = 0.30, P = 0.01), subcutaneous fat (r = 0.37, P = 0.002), insulin 
(r = 0.25, P = 0.04) and HOMA (r = 0.31, P = 0.01). We observed no correlation 
between the changes of saturated fat intake and liver fat (r = 0.18, P = 0.14). Next, 
we performed a multivariate regression analysis of seven selected parameters 
(changes in subcutaneous fat, FGF-21, apoC-III, saturated fat intake, fructose 
intake, DNL and total fat intake) to test their explanatory power for changes of 
liver fat in response to the diet intervention. The whole model explains 27% of the 
variance (adjusted R-squared), but no individual variable explained more than 5% 
of the variance alone. To further elucidate the mechanisms for the responses of 
liver fat to the diet intervention, we divided the subjects into three groups 
according to their change in liver fat after fructose. Group 1 (n = 22) had reduced 
liver fat content (from 7.2 ± 1.4% at baseline to 5.5 ± 1.3% after fructose feeding), 
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Group 2 (n = 20) had no or minimal liver fat change, and Group 3 (n = 29) gained 
liver fat (from 8.5 ±1.2% to 11.2 ± 1.2%). Adverse changes of cardiometabolic 
risk factors were most common in Group 3 (Table 13). Next, we analyzed 
differences in diet that could explain the different responses between Group 1 and 
Group 3. We showed that subjects who gained most liver fat had slightly lower 
fructose intake at baseline than subjects who lost liver fat (11.0 ± 1.3 g/L vs. 16.4 
± 2.0 g/L). In addition, these subjects increased significantly calorie intake (P = 
0.03) probably due to less clear reduction in saturated fat intake. However, the 
actual difference of changes between the two groups showed only a nonsignificant 
trend towards higher intake of energy and saturated fat after fructose feeding.  To 
clarify the impact of genetic polymorphisms, we analyzed three polymorphisms 
that are known to modify the liver fat metabolism: PNPLA3, TM6SF2 and 
MBOAT7. We showed that increased numbers of risk alleles correlated with 
increased liver fat content before diet intervention (Figure 4a). However, there 
was no difference in the number of risk alleles between Group 1 and Group 3 
(Fig. 4b). Furthermore, there were no differences in liver fat change in response to 
the diet intervention between individuals with and without risk alleles (Fig. 4c). 
Thus, these three polymorphisms did not explain the different responses between 
Group 1 and Group 3.  
 
Effect of fructose feeding on cardiometabolic risk markers and hepatic lipid 
metabolism. We next analyzed the impact of the diet intervention on postprandial 
lipid responses. At baseline, plasma TG and apoB48 levels increased at early time 
points after the fat-rich meal (Figure 5). Importantly, baseline apoC-III showed  
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Table 13. Cardiometabolic risk factors in subjects with reduced or increased liver fat. Group 1 (n = 22) had reduced liver fat content (from 
7.2 ±1.4% at baseline to 5.5 ±1.3% after fructose feeding) and Group 3 (n = 29) gained liver fat (from 8.5 ±1.2% to 11.2 ± 1.2%). Data are 
shown as mean ± SD. P-values have been calculated using the Wilcoxon signed-rank test and refer to differences between baseline and 
after fructose intervention 
 
Significant of p-values <0.05 are bold. 
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Figure 4. The different response to the diet intervention is independent from 
PNPLA3, TM6SF2 and MBOAT7. a) Increased number of risk alleles associates 
with increased liver fat content before diet intervention. b) No differences in the 
number of risk alleles between Group 1 and Group 3. Group 1 (n = 22) had 
reduced liver fat content (from 7.2 ± 1.4% at baseline to 5.5 ±1.3% after fructose 
feeding) and Group 3 (n = 29) gained liver fat (from 8.5 ± 1.2% to 11.2 ± 1.2%). 
c) Individuals without or with risk allele do not have differences in liver fat 
change in response to the diet intervention. Data are shown as mean value and 
standard deviation (continuous traits) or as percentage. P value was calculated by 
linear regression analysis (a), ordinal regression (b) or Mann–Whitney 
nonparametric test for independent samples (c). Risk alleles: TM6SF2 T; 
PNPLA3 G; MBOAT7 T. 
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strong positive correlations with both baseline TG (Figure 6a) and TG AUC 
(Figure 6b). At baseline, both fasting TG and TG AUC (after a fat-rich meal) 
correlated negatively with plasma adiponectin (r = -0.37 and -0.42, respectively, P 
< 0.001), but the correlation between TG AUC and liver fat content was only 
modest (r = 0.30, P = 0.01). The responses of both plasma total TG and apoB48 
levels to the fat-rich meal were higher after fructose feeding (Figure 5). Both 
plasma TG and apoB48 were augmented by fructose feeding for up to 120 min 
after the high-fat meal. The overall responses of plasma total TG, measured as 
AUC as well as iAUC were increased after fructose feeding. We did not observe 
any significant changes in AUCs of TG and apoB48 in chylomicrons, VLDL1 or 
VLDL2 fractions after fructose feeding. Fructose feeding induced significantly 
higher systolic blood pressure values (but not heart rate), fasting insulin and 
HOMA index (Table 11). Both fasting serum TG levels and apoC-III increased 
significantly after fructose intervention (Table 11). Importantly, apo CIII showed 
strong positive correlations with TG and postprandial TG AUCs after fructose 
feeding (Figure 6c,d). In addition, the apo CIII change after fructose feeding 
correlated significantly with changes of TG and TG AUCs (Figure 6e,f). Fructose 
feeding was not associated with significant changes in fasting FFA, FGF-21 or 
uric acid concentrations (Table 11), or in glucose or insulin AUCs during an 
OGTT (data not shown). Notably, we observed a strong correlation between liver 
fat and FGF-21 values before (Figure 7a) and after (Figure 7b) fructose feeding. 
Fructose feeding resulted in significant increases in DNL in the fasting state (12.3 
vs. 16.5% de novo palmitic acid in VLDL1, P < 0.01) and also at 4 and 8 h 
postprandially. In contrast, fructose feeding resulted in a significant decrease in  
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fasting levels of β-hydroxybutyrate (P = 0.005), a surrogate marker of hepatic 
lipid β-oxidation. We further observed an inverse relationship between the 
changes in DNL and β-hydroxybutyrate in response to fructose intervention (r = -
0.42, P = 0.002). Importantly, the increase in DNL correlated positively with the 
respective change of postprandial TG AUC (r = 0.43, P = 0.001). Thus, the 
fructose-stimulated DNL may contribute to the increased postprandial TG 
responses. We next selected seven variables (changes of apo CIII, DNL, insulin, 
HOMA, weight, saturated fat intake and total fat intake) and tested their 
explanatory power for TG AUC change after fructose intervention in a 
multivariate regression analysis. The whole model explains 73.7% of the variance 
(adjusted R-squared). Multiple regression analysis identified the apo C-III change 
as the strongest predictor for the change of TG AUC followed by those of DNL, 
insulin and HOMA change. Importantly, apo C-III alone explained 59% of the 
variance, whereas DNL alone explained 16% of the variance in changes in TG 
AUC. 
Figure 5. Responses of plasma TG and apoB48 after a fat-rich mixed meal before 
and after fructose feeding. The P-values have been calculated using the Wilcoxon 
signed-rank test. *P < 0.05. The AUC before versus after for TG (a) and (b) 
apoB48 are shown. 
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Figure 6. Correlations of plasma apoC-III and TG and TG AUCs after a fat-rich 
meal, before (a + b) and after fructose feeding (c + d). ApoC-III changes versus 
TG and TG AUCs changes after fructose feeding (e + f). Correlation coefficients 
and their corresponding P-values were calculated using Spearman’s rank test 
 
 
Figure 7. Correlations of fasting plasma FGF-21 and liver fat content before (a) 
and after fructose feeding (b). Correlation coefficients and their corresponding P-
values were calculated using Spearman’s rank test. 
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Discussion 
A central finding in this study is that a real-world daily consumption of fructose-
sweetened beverages for 12 weeks had significant but modest adverse effects on 
multiple cardiometabolic risk factors. We also report that the fructose 
consumption significantly increased liver fat content and hepatic DNL and 
decreased levels of β-hydroxybutyrate (indicating decreased hepatic b-oxidation). 
Interestingly, the individual changes of liver fat were highly variable in subjects 
with the same weight change (Figure 3). However, the average relative increase 
in liver fat (10%) was more pronounced than the significant but low relative 
increases in weight (1.1%) and waist circumference (0.5%). Importantly, the 
adverse changes of cardiometabolic risk factors seemed to cluster more with the 
increase in liver fat than with the weight gain. Our intervention was intended to be 
hypercaloric, in which the fructose-sweetened beverages were consumed in 
addition to the habitual diet. The fructose dose (75 g/day, corresponding to 13% 
of the energy intake) was slightly higher than the mean consumption of fructose in 
the United States (55 g/day) [215, 216], but comparable to the dose that is 
habitually consumed by some high risk groups, including adolescents in Western 
societies [217]. Despite our intention to undertake a hypercaloric intervention 
study, the reported energy intake was not significantly higher after fructose 
intervention despite the small but significant increase in weight and waist 
circumference. The fact that fructose sweetened beverages provided an excess of 
300 calories but the daily energy intake increased only by an average of 54 
calories indicates that the study subjects reduced their energy intake from other 
food and beverages. Indeed, the subjects reported significantly decreased intake of 
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saturated fat and sucrose during fructose feeding. Recently, it was reported that 
10-week consumption of fructose-sweetened beverages was linked to reduced 
resting energy expenditure [218]. This would further increase weight gain if total 
energy intake is not reduced accordingly. Earlier studies have shown that the size 
and distribution of fat depots varied significantly also according to the saturation 
of the fat that was consumed [219]. Rosqvist et al. recently tested whether 
overeating a diet rich in additional PUFA would reduce formation of ectopic fat 
compared with overeating a diet high in saturated fatty acids (SFA) [220]. The 
results show that the SFA diet induced a significant increase in liver fat relative to 
the PUFA diet [220]. In our study, the subjects reduced their intake of dietary 
saturated fat, which may have counteracted the stimulatory effect of fructose 
intake on the liver fat accumulation. The reduction in saturated fat was more 
prominent in subject who lost liver fat than in those who gained liver fat. A 
critical question is whether the fructose consumption directly increased liver fat 
content? Enhanced DNL is reported to contribute significantly to the hepatic 
triacylglycerols in NAFLD [221]. Fructose (and sucrose in sugar sweetened 
beverages) acutely and chronically promotes hepatic lipogenesis by stimulating 
SREBP-1c and ChREBP [19,192,198,199,205] and suppresses mitochondrial fatty 
acid oxidation [95,96,197]. These processes synergistically promote hepatic 
storage of lipids and secretion of triglyceride rich VLDL particles [200, 206, 208, 
222-224]. Our observation that DNL was increased during fructose feeding for 12 
weeks is consistent with earlier shorter studies [225-228] and compliments the 
study by Stanhope et al. [223] showing that increased DNL is maintained during 
chronic intake of high-fructose liquids. In our study, fructose beverages reduced 
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β-hydroxybutyrate (a surrogate marker of hepatic lipid oxidation). Cox et al. 
recently reported decreased postprandial fat oxidation in overweight/obese 
subjects who consumed fructose beverages at 25% of energy requirements for 10 
weeks as part of energy balanced ad libitum diet [218]. These changes of energy 
fluxes were not seen in subjects consuming glucose-sweetened beverages at 25% 
energy requirements [218]. Notably, DNL also increased significantly, but liver 
fat changes were not quantitated in these studies [218,223]. Fructose is absorbed 
via the portal vein and delivered at much higher concentrations to the liver 
compared to other tissues [207]. Thus, high fructose consumption forces the liver 
to adapt its metabolism against liver toxicity. Key pathways that could be altered 
include the storage of excess lipids in hepatocytes resulting in steatosis, and the 
packaging of triacylglycerols in VLDL to remove extra lipids from the liver. The 
fact that increases in DNL correlated with increases in postprandial TG AUC after 
fructose intervention suggests that there is a direct link between increased hepatic 
triacylglycerol synthesis and assembly and secretion of VLDL. Increased fat 
oxidation is another adaptive mechanism that prevents liver fat accumulation 
[196]. Our observation of a reduction in β-hydroxybutyrate during fructose 
feeding indicates reduced ability of the liver to shuttle fatty acids to oxidation and 
ketone body formation. FGF21 is considered to be a major regulator of body 
energy metabolism promoting fatty acid oxidation but suppressing DNL 
[229,230]. We observed strong correlations between fasting FGF-21 levels and 
the liver fat content in line with earlier studies [231,232] and a negative 
correlation with b-OH butyrate (r = -0.28, P < 0.017). We observed a 
nonsignificant trend for increase in fasting FGF-21 levels after fructose feeding in 
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these abdominally obese subjects. Fructose has earlier been reported to increase 
acutely the response of FGF-21 [233]. In this study, FGF-21 increased about 3.4-
fold after acute intake of 75 g of fructose, but so far no data exist on the effects of 
more chronic intake of fructose. The lack of effect on fasting uric acid could be 
due to the fact that the greatest effects of fructose-containing sugars on uric acid 
are observed in the postprandial and not the fasting state [234]. Postprandial 
dyslipidemia is a key feature of the atherogenic lipid profile in abdominally obese 
subjects and is exaggerated in those with hypertriglyceridemia. Acute and short 
term as well as more chronic intake of high fructose promotes elevation of both 
fasting and postprandial triglyceride levels in healthy subjects as well as in those 
with the metabolic syndrome [100, 105, 235-241]. The data from meta-analyses 
suggest that these effects on postprandial lipids are induced by both hypercaloric 
and isocaloric diets [242,243]. We performed here thorough analyses of 
triglycerides, apoB48 and apoB100 in serum and different triglyceride-rich 
lipoprotein fractions to clarify the responses to fructose feeding. We showed that 
fructose feeding aggravated the increases in both total triglycerides and apoB48 at 
early time points after a fat-rich meal. However, the differences in total responses 
of plasma triglycerides and apoB48 AUC after the fructose feeding remained 
marginal. Interestingly, we observed a significant rise of apo C-III during fructose 
feeding in line with recent results by Stanhope et al. [244]. These data are 
consistent with the possibility that fructose, like glucose, stimulates the expression 
of apoC-III via ChREBP. We also showed that apoC-III was a strong predictor for 
postprandial serum TG AUC, both before and after fructose feeding, supporting a 
role for apo C-III in the clearance of triglyceride-rich lipoproteins [245]. Our 
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study has several strengths. First, the study group was larger than in any previous 
mechanistic study using magnetic resonance examinations and stable isotopes to 
elucidate the adverse effects of fructose on cardiometabolic risk factors. Secondly, 
the study subjects were genotyped for three key risk alleles for fatty liver 
development to determine whether they played a role in liver fat responses to 
fructose. Thirdly, the duration of the study was longer than in earlier acute or 
short-term mechanistic studies. Fourthly, the amount of fructose was similar to the 
habitual consumption in the USA and Middle East. An important limitation is that 
we do not have a control group to specifically disentangle the metabolic effect(s) 
of weight gain versus fructose. Additional potential weaknesses are that fructose 
served in beverages may not induce the same metabolic responses as when 
fructose is ingested as a part of sucrose or in natural compounds; pure fructose 
may be absorbed less efficiently than sucrose [217]. We cannot confirm that the 
study subjects really consumed the daily recommended dose of fructose as our 
compliance assessment was indirect and did not include a measure of blood 
fructose concentration. Overall the reported compliance was good when 
recognizing all caveats. Both poor adherence to fructose intake and less 
absorption of fructose would result in less robust metabolic effects of fructose 
consumption than actually were seen in our study. 
In conclusion, our data demonstrate that the adverse cardiometabolic effects of 
fructose consumption over a 12-week period were significant but modest. 
However, these detrimental cardiometabolic effects may be exacerbated over a 
longer period time as occurs in the real life. Thus, our results should be interpreted 
in the context of chronic overconsumption of sugar-sweetened beverages 
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containing fructose amongst heavy consumers who are common across the globe. 
Our study also indicates that there are remarkable individual differences in 
susceptibility to visceral adiposity/liver fat deposition and that such differences 
play a role in modulating the health hazard associated with chronic consumption 
of fructose-containing beverages. 
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5.3. MEDEA trial 
Background 
NAFLD is the most common chronic liver disease in the industrialized world and 
its prevalence has been reported to be in the 15–30% range in the general 
population in various countries. The prevalence approaches 70–90% in people 
with obesity and T2DM and it can be considered the hepatic component of the 
metabolic syndrome [246]. Patients with T2DM are particularly susceptible to 
more severe forms of NAFLD [246,247], by mechanisms that are still 
incompletely understood, and have a higher progression to hepatocellular 
carcinoma [248,249]. Furthermore, the presence of NAFLD in T2DM aggravates 
the metabolic profile, insulin sensitivity, and dyslipidemia [250]. It is important to 
underline that NAFLD in T2DM is also related to an increased prevalence of 
cardiovascular events and microvascular complications including chronic kidney 
disease and retinopathy [251,252]. Lifestyle modifications remain the therapy of 
choice for NAFLD also in individuals with T2DM. In recent years, there has been 
a growing interest in studies concerning the beneficial effects of dietary nutrients 
on NAFLD since these components have several advantages such as being widely 
available, while having low or minimal side effects.  However, few studies 
examining optimal dietary strategies for NAFLD in T2DM are available. 
As discussed above, data are reasonably convincing as for the possible effects of 
dietary macronutrients on liver fat content. In fact, SFA increase liver fat content 
and replacing SFA with MUFA or n-6 PUFA reduces liver fat, while the 
effectiveness of n-3 PUFA supplementation is still controversial. In terms of other 
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dietary components as polyphenols and micronutrients, beneficial effects would 
refer especially to liver inflammation and fibrosis more than to fat content.  
Consequently, it is conceivable that a diet rich in all micro- and macronutrients (a 
Portfolio diet) with beneficial effects on NAFLD is more effective than a 
monofactorial dietary intervention, such as the only increase of MUFA. So far, no 
studies have evaluated the effect of this kind of diet naturally rich in low GI 
carbohydrates, vegetable fiber, MUFA, n-3 and n-6  PUFA and polyphenols on 
liver fat in patients with T2DM. 
 
Aim 
To evaluate the effects of a 8-weeks intervention with an isoenergetic Portfolio 
diet rich in MUFA, n-3 and  n-6 PUFA, prebiotic fibre and polyphenols, and with 
low GI carbohydrates versus an isoenergetic diet rich in MUFA on NAFLD in 
patients with T2DM. 
 
Materials and Methods 
Subjects. Thirty-one individuals of both sexes, aged 35–75 y, with a large BMI (in 
kg/m2; 25–35) and waist circumference (men ≥ 102 cm; women ≥88 cm) were 
recruited from patients referred to the Diabetes outpatient clinic of the Federico II 
University Hospital. Health status and medical history were assessed by 
interviews, clinical examinations, and routine laboratory tests. Inclusion criteria 
were as follows: T2DM in satisfactory blood glucose control with diet or drug not 
affecting liver fat content (metformin, DDP4-i, sulfonylurea, repaglinide), stable 
weight (±3 kg) over the preceding 3 months, glycated hemoglobin <7,5%, 
  
76 
 
evidence of steatosis both on ultrasonography at ultrasonography, stable therapy 
with lipid-lowering drugs, LDL cholesterol < 130 mg/dL and serum triglycerides 
<350 mg/dL. Exclusion criteria were as follows: treatment with insulin or other 
glucose-lowering drugs affecting liver fat content (as GLP-1 analogues, SGLT2 
inhibitors, insulin). Any acute or chronic liver disease of genetic or infectious 
origin, any acute or chronic disease seriously affecting the health status, use of 
alcoholic beverages (more than 1 serving/day), hormonal therapy. The study 
design was approved by the local ethics committees, and each subject gave 
written informed consent before participation in the study. All procedures were 
performed in accordance with the Declaration of Helsinki for clinical trials. 
  
Study design. The study was based on a randomized, controlled, parallel group 
design and consisted of a 2–4 week run-in period, during which the participants 
were stabilized on their own diet, and a 8-wk test period. At the end of the run-in 
period, the participants were randomly assigned to one of two groups: one group 
consumed a Portfolio diet (naturally rich in MUFA, n-3and n-6 PUFA, prebiotic 
fibre, polyphenols, vitamins, and low GI carbohydrates) and the other group 
consumed a MUFA diet (naturally rich in MUFA). The randomization was 
performed with stratification for sex, age and BMI (25–30, 30–35 kg/m2), and 
T2DM therapy by use of random allocation software. Allocation was carried out 
by personnel not involved in the study; therefore the investigators and the 
dieticians were aware of the group allocation of the participant only after the 
randomization process had been performed. During the study, participants were 
advised not to change their body weight and lifestyle habits such as exercise and 
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alcohol consumption and not to change their medications unless necessary. As 
shown in Table14, the assigned diets differed only in n-3 and n-6 PUFA, vitamin 
D, vitamin C, glycemic index, glycemic load, fibre, and polyphenol contents and 
were similar in all other characteristics as macronutrient composition, MUFA and 
other micronutrients. Dietary composition was derived from the tables of the 
Italian National Research Institute for Food and Nutrition [253], whereas 
polyphenol contents and the Oxygen Radical Absorbance Capacity index were 
calculated according to USDA tables [254]. The main dietary sources of 
carbohydrates were represented by based on wholegrain products including whole 
wheat bread, whole wheat pasta, barley kernels, legumes in the Portfolio diet, 
while MUFA diet contained commercial products based on refined cereals such as 
wheat bread, rice, pasta, and breakfast cereals.  The main dietary source of MUFA 
was extra-virgin olive oil in both diet, while the main sources of n-3 and n-6 
PUFA were represented by were salmon, dentex, and anchovies and nuts in the 
Portfolio diet. Main source of polyphenols were represented by decaffeinated 
green tea, decaffeinated coffee, artichokes, onions, spinach, rocket. The initial 
assigned energy intake of the diet was determined based on the individual’s 
habitual energy intake evaluated by a 7-d food record, adjusted for body weight 
and clinical judgment of the dietitians, in order to take care of a possible 
underreporting, common in overweight/obese individuals. To improve dietary 
adherence, meals and beverages were provided to the participants for the whole 
study period in amounts sufficient to cover their household consumption. Meals 
were prepared in a qualified catering service under the surveillance of the 
dietitians. Adherence to diets was evaluated by a 7-d dietary record at baseline, 4 
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wk, and 8 wk and was reinforced by the dietitians through counseling every week 
and phone calls every 2–3 d. Participants allocated to the two diet were considered 
compliant with the treatment if intakes were > 80% of those assigned. 
 
Table 14. Nutrient composition of the experimental diets. 
 MUFA Portfolio 
Energy Kcal/day 1972 1977 
Proteins % TE 18 18 
Lipids % TE 41 41 
SAFA % TE 7 6 
MUFA % TE 28 26 
PUFA % TE 4 5,8 
n-3 g/day 1,1(0,5%) 2,6 (1,2%) 
n-6 g/day 7,4 (3,4%) 9,6 (4,4%) 
Cholesterol mg 184 121 
Carbohydrates % TE 41 41 
Sugars % TE 11 9,8 
Fiber (g/1000 Kcal) 10 24 
Glycemic Index (%) 58,5 47 
Glycemic Load - 125 94 
Vitamin E mg 22 23,6 
Vitamin D mcg 1 5,3 
Vitamin C mg 88 254 
Total ORAC μmolT 7501 14187 
Polyphenols mg 376 2715,5 
 
ORAC= Oxygen Radical Absorbance Capacity; TE= Trolox Equivalent 
 
Experimental procedures. At baseline and after the 8-wk intervention, body 
weight, height, waist circumference, and blood pressure were measured according 
to standardized procedures. After a 12-h overnight fast, blood samples were 
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collected for the measurement of plasma concentrations of glycated hemoglobin, 
ALT, AST, and GGT.  
 
Laboratory methods. Glycated hemoglobin was determined by high-performance 
liquid chromatography (HPLC).  ALT, AST, and GGT activities were determined 
by colorimetric methods according to the International Federation of Clinical 
Chemistry recommendations.  
 
Liver fat evaluation. Liver fat content was measured by 1H-MRS performed on a 
3T MR scanner (Intera; Philips Medical Systems, Best, the Netherlands) equipped 
for proton spectroscopy acquisitions in the morning at fasting, at baseline and 
after the 8-wk intervention. Sagittal, coronal, and axial slices covering the whole 
liver were preliminarily taken to position the spectroscopy acquisition voxel. A 
single voxel of 8 cc (2×2×2mm2) was placed within the right lobe avoiding major 
blood vessels, intrahepatic bile ducts, and subcutaneous fat tissue. The proton 
spectrum was acquired using an eight-channel phased array body coil after 
shimming over the volume of interest using an unsuppressed water PRESS 
sequence with the following parameters: TE = 35 ms, TR = 3000 ms, NSA=1, 
sprectral width 2000 Hz. Total spectra acquisition time was 16 s and thus acquired 
in breath hold to avoid movement artifacts and spectra broadening. Spectra were 
analyzed using LCModel software (version 6.2-1; http://s-provench-er.com) that 
fits in vivo metabolite spectra using model resonances acquired under comparable 
scanning conditions from multiple compounds in standard phantom solutions. 
Concentration values in arbitrary units of water peak (signal of water) and the sum 
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of lipid peak at 1.3, 0.9, and 1.6 ppm (signal of fat) were considered for fat liver 
quantification, including both methyl and methylene groups of triglyceride 
molecule. Signal decay was corrected for the different T2 decay of water and fat 
using mean T2 relaxation times of 50 and 60 ms for water and fat, respectively. 
Hepatic fat percentage was calculated using the following formula: 100 · Sf ⁄ (Sf + 
Sw) [255], where Sf is signal of fat and Sw is signal of water. These values 
represent a relative quantity of water and fat in the volume of interest. To convert 
these values into absolute concentrations (weight per volume) expressed as 
percent fat, equations validated by Longo et al. [256] were applied. 
 
Sample size calculation and statistical analysis. In order to detect a 30% 
difference in liver fat content between treatments with a 80% power at 5% 
significance level, 46 patients (23 for each group) had to be studied. The expected 
changes in liver fat content after treatment correspond to the differences observed 
between obese patients with or without T2DM in a previous study [53]. 
Energy intake and nutrient composition at the end of the run-in period and during 
the intervention were calculated from the food records; the intakes during the 
intervention were expressed as mean of three food records completed at 4, 8 and 
12 weeks.  The results for continuous variables were presented as mean ± standard 
error (mean ± SEM), unless otherwise stated. Variables with skewed distributions 
by Shapiro-Wilks test were normalized with a logarithmic or square root 
transformation. 
A paired-samples t test was used to examine the changes within each group. 
Repeated measures ANOVA was used to evaluate differences between Portfolio 
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diet and Mufa diet calculated as absolute changes (8 wk value - baseline value). A 
t-test for unpaired data was used for the differences in liver fat content measured 
as percent variation (end values − baseline values × 100/baseline values). 
For all analyses, the level of statistical significance was set at p = 0.05 (two tails). 
Data were analyzed using SPSS for Windows 20.0 (SPSS Inc., Chicago IL). 
 
Preliminary results 
The preliminary results on the first 31 individuals are reported. 
Characteristics of participants at baseline. As shown in Table 15, the participants 
allocated to the two intervention groups were comparable for age, BMI, waist 
circumference, blood pressure, diabetes drug treatment, plasma values of  HbA1c, 
AST, ALT, GGT, as well as liver fat content. 
 
Table 15. Baseline characteristics of the 2 groups of participants in the dietary 
intervention study. 
 
  MUFA (n=15) 
Portfolio 
(n=16) P 
Sex (M/F)   11/4 11/5 
 Age (y)  61.7±5.2 64.4±56.5 0.213 
Body weight (kg)  87.0±14.6 84.2±9.7 0.528 
BMI (kg/m
2
) 30.7±3.4 31.0±3.3 0.793 
Waist circumference (cm)  107.2±8.9 105.5±9.2 0.608 
Systolic blood pressure (mm Hg)  129.1±11.7 135.1±33.6 0.518 
Dyastolic blood pressure (mm Hg)  79.8±7.4 80.5±7.5 0.797 
HbA1c (%) 6.6±0.5 6.4±0.5 0.306 
Liver fat (%) 11.5±9.6 8.6±8.0 0.371 
AST (U/l) 21.0±10.2 18.7±6.7 0.461 
ALT (U/l) 28.9±12.6 22.3±10.9 0.132 
GGT (U/l) 27.8±13.8 29.2±15.0 0.792 
 
Mean ± SD (all such values). 
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Compliance with dietary intervention. The composition of the diets strictly 
reflected the dietary composition assigned per protocol in the two groups (data not 
show). As expected, the diets were significantly different in n-3 and n-6 PUFA, 
vitamin D, vitamin C, GI carbohydrates, glycemic load, fibre, and polyphenol 
content. No differences in macronutrients content were observed between the 2 
dietary groups. All subjects were within the ranges of intakes defined for good 
compliance for each dietary component. 
 
Effects of dietary intervention on anthropometric parameters, blood pressure, 
HbA1c, and liver enzymes. At the end of the intervention, there was a small 
significant weight loss with both diets (Mufa Diet: -0,6 ± 0,3 kg vs. Port Diet:- 1.4 
± 0.5 kg), but the difference in weight change between the groups was not 
significant (p = 0.232). Similarly, at end of the intervention, there was a small 
significant reduction in BMI with both diets (Mufa Diet: -0,2 ± 0,1 m/kg2 vs. Port 
Diet:- 0.5 ± 0.1 m/kg2), but the difference between the groups was not significant 
(p = 0.202). 
No differences in waist circumference, blood pressure, HbA1c, AST, ALT, GGT 
at end of intervention in the two groups and between groups were observed 
(Table 16 ). 
 
Effects of dietary intervention liver fat. In the absence of baseline differences in 
hepatic fat content between the two groups, liver fat did not change significantly 
after Mufa diet (11.5±9.6 vs 10.0±9.3 %; P=0.071), while it significantly 
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decreased after the Portfolio Diet (8.6 ± 8.0 vs. 4.8 ± 4.7%; P = 0.006), with a 
significant difference between groups (P= 0.022) (Table 16). 
 
Table 16. Anthropometrics, metabolic characteristics, and liver fat before and 
after the 8-week interventions. 
 
 
 MUFA diet (n=15) PORT diet (n=16)  
baseline 8-week Δ baseline 8-week Δ p for 
Δ
§
 
Body weight (kg) 87.0±14.6 86.3±14.3 -0.6* 84.2±9.7 82.7±9.4 -1.4* 0.720 
BMI (kg/m
2
) 30.9±3.4 30.4±3.3 -0.2* 31.0±3.2 30.4±3.2 -0.5* 0.850 
Waist circumference (cm) 107.2±8.9 106.9±9.0 -0.3 105.5±9.2 104.7±9.0 -0.7 0.400 
Systolic blood pressure (mmHg) 129.1±11.7 127.4±14.4 -1.6 135.1±33.5 127.6±11.8 -7.4 0.760 
Diastolic blood pressure (mmHg) 79.8±7.3 75.3±9.7 -4.5 80.5±7.4 75.9±8.9 -4.6 0.840 
HbA1c (%) 6.6±0.5 6.5±0.5 -0.1 6.4±0.5 6.2±0.6 -0.2 0.300 
Liver fat (%) 11.5±9.6 10.0±9.3 -1.5 8.6±8.0 4.8±4.7 -3.8* 0.002 
AST (U/l) 21.0±10.2 21.0±8.5 0.0 18.7±6.7 16.1±4.9 -2.6 0.059 
ALT (U/l) 28.9±12.6 25.3±8.6 -3.6 22.3±10.9 21.8±9.2 -0.5 0.810 
GGT (U/l) 27.8±13.8 25.6±12.0 -2.2 29.2±15.0 26.3±16.3 -2.9 0.830 
 
Mean ± SD (all such values), Δ: change of the parameters calculated as 8 week-baseline values.  
*p < 0.05 paired sample t-test (8-week vs. baseline), corrected for body weigth loss.                  
§Differences between the two groups (MUFA vs. PORT) were evaluated by one way ANOVA. 
 
Measured as percent variations (end values − baseline values × 100/baseline 
values), hepatic fat was significantly reduced by the Portfolio diet (−38.2%) more 
than by the Mufa Diet (−15.3%) (P=0.04 by ANOVA) (Figure 8). 
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Figure 8. Percent changes (end values − baseline values × 100/baseline values) in 
liver fat content after the 8-week intervention in the two groups. 
 
 
Data are expressed as means ± SE; *P < 0.05 vs. Portfolio diet. 
 
Discussion 
Preliminary results our trial have demonstrated that in just 8 weeks, a Portfolio 
diet naturally rich in n-3 and n-6 PUFA, prebiotic fibre, polyphenols, and with 
low GI carbohydrates, can induce a relative reduction in liver fat, compared with a 
diet rich in MUFA.  
To our knowledge, this the first trial to demonstrate in a randomized, controlled 
study, a reduction in liver fat with a Portfolio diet in T2DM. We have compared 
the Portfolio diet with a naturally rich MUFA diet since our previous data showed 
that an isocaloric diet enriched in MUFA in replacement of saturated fat and fiber 
was associated with a clinically relevant reduction of hepatic fat content in T2DM 
[53]. 
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As discussed above, data are reasonably convincing as for the possible effects of 
dietary macronutrients and micronutrients on liver fat content. In fact, SFA 
increase liver fat content and replacing SFA with MUFA or n-6 PUFA reduces 
liver fat, while the effectiveness of n-3 PUFA supplementation is still 
controversial. In terms of other dietary components as polyphenols and 
micronutrients, beneficial effects would refer especially to liver inflammation and 
fibrosis more than to fat content. Consequently, we have demonstrated that the 
combination of these foods in a dietary model such as a "Portfolio diet", inspired 
to a Mediterranean Diet model in which more beneficial dietary component are 
included could be more effective in the prevention and treatment of NAFLD, 
compared to a single dietary component.  
In spite of isoenergetic study design, a small significant weight loss with both 
diets has been observed, however, this did not influence the results because 
analyses were corrected for body weight loss. 
Based on our preliminary results, it is conceivable to infer that a diet rich in all 
micro- and macronutrients with beneficial effects on NAFLD is more effective 
than a monofactorial dietary intervention, such as the only increase of MUFA. 
The lack of changes seen in the liver function tests may have been a result of the 
small sample size or the short duration of the study; however, it does demonstrate 
a lack of sensitivity of these tools as markers of liver inflammation, as it has been 
previously demonstrated [33]. 
Taking into account the different components of our Portfolio diet, different 
mechanism could explain the liver fat reduction observed. From a mechanistic 
point of view and as evidenced both in animal and human studies, the hepatic fat-
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lowering effects of n-3 and n-6 PUFA could be mainly due to their anti-
inflammatory and anti-fibrotic properties, to the up-regulation of hepatic lipolysis 
and fat oxidation and to the down-regulation of hepatic lipogenesis [65]. MUFAs 
may exert their beneficial effects on liver steatosis through the improvement of 
postprandial hepatic fatty acid oxidation [48] as well as through the stimulation of 
lipoprotein lipase activity in adipose tissue and the resulting enhancement of 
triglyceride (TAG) clearance [57-60]. In contrast, the effects of fibre intake on 
NAFLD could be associated with their ability to modulate the gut microbiota, 
leading to the subsequent attenuation of de novo fatty acid synthesis in the liver 
[80]. On the other hand, low GI carbohydrates have been shown to induce a lower 
rise in postprandial glucose and insulin levels, leading to decreased activation of 
hepatic lipogenesis [79]. Regarding vitamins, those that have been demonstrated 
to be more effective for NAFLD patients are vitamin E and vitamin D. 
Specifically, different studies have reported that the mechanisms of action of these 
vitamins include decreased oxidative stress, lipid peroxidation, inflammation, 
fibrosis, lipid uptake and lipogenesis [138-141,157]. Likewise, the metabolic 
processes involved in the anti-steatotic effects of polyphenols could be the 
inhibition of hepatic lipogenesis, oxidative stress and inflammation and the 
improvement of fatty acid oxidation [122-125]. Finally, by shaping gut microbiota 
composition and decreasing endotoxaemia, probiotics have been shown to 
decrease liver oxidative stress, inflammation and lipogenesis [80]. 
This study has some strengths and limitations. This was a randomized controlled 
trial with a rigorous follow-up of dietary adherence. Hepatic fat content was 
measured by the gold standard 1H-MRS. A limitation is that only Caucasian 
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patients in good metabolic control were studied, and therefore our results may not 
be extended to T2DM patients of other ethnic groups or with poorer control. 
Nevertheless, there are no indications that worse metabolic control could 
negatively influence the effects of a Portfolio diet on hepatic fat content. 
Therefore, in light of our new findings, we suggest that an increase in the intake 
of MUFAs and also n-3 PUFAs, particularly as a replacement for saturated fat and 
as a higher proportion of low GI carbohydrates in the diet, is beneficial to NAFLD 
patients. 
These preliminary results are clinically relevant and have implications for the 
nutritional management of fatty liver, suggesting that a Portfolio diet might be the 
preferential approach. In fact it is very likely that the “optimal diet” for NAFLD 
should be based on the synergic and/or complementary action of different food 
compounds able to act both on the deposition of excess fat in the liver and the 
other pathways leading from liver fat deposition to NASH and fibrosis.  
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6. CONCLUSIONS 
The aim of my research project, developed in these three years, has been to 
evaluate firstly the relationships between liver fat content and metabolic, 
inflammatory and nutritional factors in individuals at high cardio-metabolic risk; 
furthermore, the adverse effects of fructose intake on liver fat content and other 
cardiometabolic risk factors in obese men has been evaluated; finally the effects 
of a Portfolio diet on liver fat content in patients with T2DM has been performed. 
In the ETHERPATS cohort we have observed that insulin resistance, systemic 
inflammation and postprandial GLP-1 were the main determinants of liver fat in 
people at high cardio-metabolic risk, explaining altogether about 30% of liver fat 
variability. The different factors implicated in the pathogenesis of NAFLD are 
also involved in the pathogenesis of atherosclerosis, suggesting that NAFLD may 
represent the tip of the iceberg of the complex metabolic derangements leading to 
CVD. 
The data of the FRUCTOSE trial demonstrate that the adverse cardiometabolic 
effects of fructose consumption over a 12-week period are significant but modest. 
However, these detrimental cardiometabolic effects may be exacerbated over a 
longer period of exposition as occurs in the real life. Thus, our results should be 
interpreted in the context of chronic overconsumption of sugar-sweetened 
beverages containing fructose amongst heavy consumers who are frequent in 
human populations across the globe. Our study also indicates that there are 
remarkable individual differences in the susceptibility to visceral adiposity/liver 
fat deposition and that such differences play a role in modulating the health 
hazard associated with chronic consumption of fructose-containing beverages. 
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Finally, the MEDEA trial demonstrates that an isocaloric Portfolio diet − naturally 
rich in MUFA, n-3 and n-6 PUFA, prebiotic fibre and polyphenols, and with low 
GI carbohydrate foods − compared with a diet enriched only in MUFA is able to 
induce a more relevant reduction of hepatic fat content in T2DM patients. 
These results are clinically relevant and have implications for the nutritional 
management of fatty liver, suggesting that a Portfolio diet  might be the 
preferential choice. In fact, it is very likely that the “optimal diet” for NAFLD 
should be based on the synergic and/or complementary action of different food 
components able to act both on the deposition of excess fat in the liver and on the 
other pathways leading from liver fat deposition to NASH and fibrosis.  
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